{
 "cells": [
  {
   "cell_type": "code",
   "execution_count": 1,
   "metadata": {},
   "outputs": [],
   "source": [
    "import os\n",
    "from langchain.text_splitter import RecursiveCharacterTextSplitter\n",
    "from langchain.vectorstores import Chroma\n",
    "from langchain.embeddings import SentenceTransformerEmbeddings\n",
    "from langchain.document_loaders import DirectoryLoader\n",
    "from langchain.document_loaders import PyPDFLoader\n",
    "from langchain.vectorstores import Qdrant\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 2,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "langchain                0.0.346\n",
      "langchain-core           0.0.11\n",
      "\n",
      "\u001b[1m[\u001b[0m\u001b[34;49mnotice\u001b[0m\u001b[1;39;49m]\u001b[0m\u001b[39;49m A new release of pip available: \u001b[0m\u001b[31;49m22.3.1\u001b[0m\u001b[39;49m -> \u001b[0m\u001b[32;49m23.3.1\u001b[0m\n",
      "\u001b[1m[\u001b[0m\u001b[34;49mnotice\u001b[0m\u001b[1;39;49m]\u001b[0m\u001b[39;49m To update, run: \u001b[0m\u001b[32;49mpip install --upgrade pip\u001b[0m\n"
     ]
    }
   ],
   "source": [
    "# !pip list | grep langchain"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 3,
   "metadata": {},
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "/mnt/d/AI/Medical-RAG-using-Meditron-7B-LLM/.env/lib/python3.10/site-packages/tqdm/auto.py:21: TqdmWarning: IProgress not found. Please update jupyter and ipywidgets. See https://ipywidgets.readthedocs.io/en/stable/user_install.html\n",
      "  from .autonotebook import tqdm as notebook_tqdm\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "client=SentenceTransformer(\n",
      "  (0): Transformer({'max_seq_length': 512, 'do_lower_case': False}) with Transformer model: BertModel \n",
      "  (1): Pooling({'word_embedding_dimension': 768, 'pooling_mode_cls_token': False, 'pooling_mode_mean_tokens': True, 'pooling_mode_max_tokens': False, 'pooling_mode_mean_sqrt_len_tokens': False})\n",
      ") model_name='NeuML/pubmedbert-base-embeddings' cache_folder=None model_kwargs={} encode_kwargs={} multi_process=False\n"
     ]
    }
   ],
   "source": [
    "embeddings = SentenceTransformerEmbeddings(model_name=\"NeuML/pubmedbert-base-embeddings\")\n",
    "\n",
    "print(embeddings)\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 4,
   "metadata": {},
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "  0%|          | 0/2 [00:00<?, ?it/s]100%|██████████| 2/2 [00:03<00:00,  1.66s/it]\n"
     ]
    }
   ],
   "source": [
    "loader = DirectoryLoader('data/', glob=\"**/*.pdf\", show_progress=True, loader_cls=PyPDFLoader)\n",
    "documents = loader.load()\n",
    "text_splitter = RecursiveCharacterTextSplitter(chunk_size=1000, chunk_overlap=100)\n",
    "texts = text_splitter.split_documents(documents)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 5,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "[Document(page_content='441 © 2 017 Indian Journal of Cancer | Pulished by Wolters Kluwer - MedknowCancer and cure: A critical analysis\\nRoy PS, Saikia BJ\\nDepartment of Medical Oncology, Dr. B. Borooah Cancer Institute, Guwahati, Assam, India\\nCorrespondence to: Dr. Roy PS, E‑mail: drpsr.roy@rediffmail.com\\nAbstract\\nCancer is one of the most dreaded diseases of the 20th century and spreading further with continuance and increasing incidence in the 21st century. \\nThe situation is so alarming that every fourth person is having a lifetime risk of cancer. India registers more than 11 lakh new cases of cancer \\nevery year, whereas, this figure is above 14 million worldwide. Is cancer curable? The short answer to this question is “Yes.” In fact, all cancers \\nare curable if they are caught early enough. Cancer cells continue to grow unless one of four things occur: (1) The cancerous mass is removed', metadata={'source': 'data/cancer_and_cure__a_critical_analysis.27.pdf', 'page': 0}),\n",
       " Document(page_content='surgically; (2) using chemotherapy or another type of cancer‑specific medication, such as hormonal therapy; (3) using radiation therapy; or (4) the \\ncancer cells shrink and disappear on their own.\\nKey Words:  Cancer, carcinogenesis, targeted therapy\\nIntroduction\\nA hundred years ago, cancer was not so common; however, \\nsince the last couple of decades, its incidence has been rising \\nalarmingly , probably due to our changing lifestyle, habits, \\nand increased life expectancy . Cancer is one of the most \\ndreaded diseases of the 20th century and spreading further \\nwith continuance and increasing incidence in the 21st century . \\nThe situation is so alarming that every fourth person is \\nhaving a lifetime risk of cancer.[1] India registers more than \\n11 lakh new cases of cancer every year, whereas, this figure \\nis above 14 million worldwide. We are constantly exposed \\nto a variety of cancer causing agents, known as carcinogens.\\nWhat is cancer? Put simply; cancer is the abnormal growth', metadata={'source': 'data/cancer_and_cure__a_critical_analysis.27.pdf', 'page': 0}),\n",
       " Document(page_content='What is cancer? Put simply; cancer is the abnormal growth \\nof cells. Cancers arise from any organ or body structure and \\nare composed of tiny cells that have lost the ability to stop \\ngrowing. Occasionally , cancer may be detected “incidentally” by \\na laboratory test or radiological routine test or for an entirely \\ndifferent reason. In general, cancer must reach a size of 1 \\ncm, or be comprised of 1 million cells, before it is detected. \\nAt this point, it may be referred to as a “‘mass,” a “growth,” \\na “tumor,” a “nodule,” a “lump,” or a “lesion.” Exceptions \\nto this general rule include cancers of the blood and bone \\nmarrow (leukemia’s and lymphomas) – which frequently do \\nnot produce a “mass,” but will be evident on laboratory tests.\\nTransformation of a normal cell into a cancerous cell is \\nprobably not such a critical event in the genesis of cancer; \\nrather it is the inability of immune cells of the body to \\nidentify and destroy the newly formed cancer cells when', metadata={'source': 'data/cancer_and_cure__a_critical_analysis.27.pdf', 'page': 0}),\n",
       " Document(page_content='identify and destroy the newly formed cancer cells when \\nthey are a few in numbers.[2] The risk of cancer is multiplied \\nin those persons, whose immune system is suppressed due \\nto any factor including chronic stress, old age, chronic \\ndebilitating disease, previous use of chemotherapy , and abuse \\nof drugs such as analgesics, antibiotics, and corticosteroids.\\nMultidisciplinary Aspects\\nCancer cells continue to grow unless one of four things \\noccur:  (1) The cancerous mass is removed surgically; \\n(2) using chemotherapy or another type of cancer -specific medication, such as hormonal therapy; (3) using radiation \\ntherapy; or (4) the cancer cells shrink and disappear on their \\nown. This last event, while extremely rare, can occur with \\nsome melanomas or some kidney cancers.\\nSurgery , radiotherapy , and chemotherapy from the \\nconventional approaches are used to treat cancer. Surgery \\nwas the first modality used successfully in the treatment of', metadata={'source': 'data/cancer_and_cure__a_critical_analysis.27.pdf', 'page': 0}),\n",
       " Document(page_content='was the first modality used successfully in the treatment of \\ncancer. It is the only curative therapy for many common \\nsolid tumors. The most important determinant of a successful \\nsurgical therapy is the absence of distant metastases and \\nno local infiltration. Chemotherapy is the administration \\nof cytotoxic agents (orally or intravenously , usually in \\ncombinations) resulting in cytotoxicity to both resting and \\ndividing cells. The objective of cancer chemotherapy is to \\nprevent cancer cells from multiplying, invading, metastasizing, \\nand killing the patient. Systemic chemotherapy is the main \\ntreatment available for disseminated malignant diseases. \\nRadiation therapy is a local modality used in the treatment of \\ncancer. Other conventional techniques used in the treatment \\nof cancer including bone marrow transplantation, peripheral \\nstem cell transplantation, hormone therapy , photodynamic \\ntherapy , cryosurgery , immunotherapy , and gene therapy .', metadata={'source': 'data/cancer_and_cure__a_critical_analysis.27.pdf', 'page': 0}),\n",
       " Document(page_content='therapy , cryosurgery , immunotherapy , and gene therapy .\\nIs cancer curable? The short answer to this question is “Y es.” In \\nfact, all cancers are curable if they are caught early enough. That \\nis the justification for screening tests (such as mammograms, \\ncolonoscopies, and Pap smear examination). When cancers are \\ncaught early , they tend to be smaller; they are thus either easier \\nto remove surgically or more likely to shrink in response to \\nchemotherapy or radiation therapy . When cancer is localized, it \\ncan be totally removed by surgery but in most of the cases, it \\nis practically impossible to detect cancer at such an early stage. \\nEarly detection is often the key to surviving any form of cancer.\\nThe diagnosis and treatment of cancer have come a long way \\nin the last 50 years. In the past, cancer, the “C-word,” was a \\ndeath sentence. Today , we can treat and cure several types of \\ncancer; however, it is evident that these cancers need to be', metadata={'source': 'data/cancer_and_cure__a_critical_analysis.27.pdf', 'page': 0}),\n",
       " Document(page_content='cancer; however, it is evident that these cancers need to be \\nfound at an early stage. More than 7 out of 10 children are \\ncured of cancer. Testicular cancer, Hodgkin’s lymphoma and \\nHow to cite this article: Roy P, Saikia B. Cancer and cure: A \\ncritical analysis. Indian J Cancer 2016;53:441‑2.This is an open access article distributed under the terms of the Creative Commons \\nAttribution‑NonCommercial‑ShareAlike 3.0 License, which allows others to remix, \\ntweak, and build upon the work non‑commercially, as long as the author is credited \\nand the new creations are licensed under the identical terms.\\nFor reprints contact:  reprints@medknow.comReview \\nArticle\\nAccess this article online\\nQuick Response Code:Website: \\nwww.indianjcancer.com\\nDOI: \\n10.4103/0019‑509X.200658 \\nPMID: \\n***\\nDownloaded from http://journals.lww.com/indianjcancer by BhDMf5ePHKav1zEoum1tQfN4a+kJLhEZgbsIHo4XMi0\\nhCywCX1AWnYQp/IlQrHD3i3D0OdRyi7TvSFl4Cf3VC1y0abggQZXdgGj2MwlZLeI= on 12/03/2023', metadata={'source': 'data/cancer_and_cure__a_critical_analysis.27.pdf', 'page': 0}),\n",
       " Document(page_content='Roy and Saikia: Cancer and cureIndian Journal of Cancer | July-September 2016 | Volume 53 | Issue 3 442many cases of leukemia can all be cured in adults with current \\ntreatments. Most skin cancers are cured with surgery . Moreover, \\nmany cases of thyroid cancer and cancer of the larynx are cured \\nwith radiotherapy . Many other types of cancer are also cured \\nif they are found early enough  – for example, 75% of breast \\ncancers found at an early stage. Of course, there is still a long \\nway to go before we can cure most cancers. The difficulty is \\nthat different cancers are caused by different things, so there \\nis not one strategy that can prevent them. They also respond \\nto different treatments, so not one kind of treatment can cure \\nthem all. Even though we can cure several types of cancers, it \\nis important to maintain vigilance about screening for cancer.\\nSome forms of cancer are curable no matter when they \\nare detected, and some are only curable if they are caught', metadata={'source': 'data/cancer_and_cure__a_critical_analysis.27.pdf', 'page': 1}),\n",
       " Document(page_content='are detected, and some are only curable if they are caught \\nat any early stage. For example, acute leukemia and some \\ntypes of lymphoma can be curable with chemotherapy . \\nCertain lymphomas such as Hodgkin’s disease require \\nradiation therapy for a cure. Other common cancers such \\nas colon cancer, breast cancer, prostate cancer, lung cancer, \\nand pancreatic cancer are all curable, but only if they are \\ndetected in early stages (Stage I or II).\\nSome cancers have high survival rates with early detection. \\nSix highly treatable cancers among others are – cancers of \\nbreast, skin (nonmelanomas), colon, prostate, testes, and \\ncervix. Most of the childhood malignancies (both solid and \\nhematolymphoid) are curable.\\nBreast cancer is the most common nonskin cancer among \\nwomen, as one out of every eight women will be diagnosed \\nin her lifetime. In patients whose breast cancer is detected \\nwhile still in localized form have a 5-year survival rate of', metadata={'source': 'data/cancer_and_cure__a_critical_analysis.27.pdf', 'page': 1}),\n",
       " Document(page_content='while still in localized form have a 5-year survival rate of \\n98%, compared with a survival rate of 72% by Stage III \\nand just 22% by Stage IV .[3,4]\\nSkin cancers (basal cell carcinoma and squamous cell \\ncarcinoma) are the most common form of all human cancers, \\nand if found early , skin cancer is nearly 100% treatable. \\nLikewise, diagnosing cervical cancer while the lesions are \\nprecancerous leads to a near 100% survival rate, but the \\nrate drops to just 32% if diagnosed in Stage III and 16% if \\ndiagnosed at Stage IV . Testicular cancer is treatable in 99% \\nof the time when detected early , but only 73% are cancer -free \\nafter 5 years if diagnosed in advanced stages. Similarly , 5-year \\nsurvival rate when colon cancer is detected early is 90%, yet \\nonly 39% of cases are diagnosed before cancer has begun to \\nspread. According to the Surveillance, Epidemiology , and End \\nResults Program, it is 98% survivable for 5 or more years', metadata={'source': 'data/cancer_and_cure__a_critical_analysis.27.pdf', 'page': 1}),\n",
       " Document(page_content='Results Program, it is 98% survivable for 5 or more years \\nif prostate cancer diagnosed at stages when the disease is \\nconfined to the prostate gland (Stage I and II).[1] The survival \\nrate drops to about 28% if diagnosed at Stage IV .\\nCancers cells not only have mutations that result in \\ndysregulated expression of oncogenes and tumor suppressor \\ngenes, but these changes result in the alteration of expression \\nof hundreds of genes. Looking at this, we have various forms \\nof “targeted” therapy directed at specific single molecular \\ntargets or a class of molecular targets in cancer cells. With \\ntargeted therapy , the specific mechanism of action of the drug \\nresults in an increase in its therapeutic index. Currently , the \\ntwo major classes of targeted therapy are the small molecule tyrosine kinase inhibitors and monoclonal antibodies (MABs). \\nImatinib, for instance, has been amazingly successful as a \\ntargeted agent directed against several members of a class of', metadata={'source': 'data/cancer_and_cure__a_critical_analysis.27.pdf', 'page': 1}),\n",
       " Document(page_content='targeted agent directed against several members of a class of \\nenzyme known as tyrosine kinases, and by that mechanism, \\nit has been phenomenally successful as a treatment of chronic \\nmyeloid leukemia and gastrointestinal stromal tumors. \\nTamoxifen is a targeted therapy directed at the estrogen \\nreceptor (ER), and it still remains a mainstay of treatment for \\nER-positive breast cancers, along with a newer class of drugs \\nknown as aromatase inhibitors.\\nCancer researchers work on developing new and more \\neffective surgery techniques, radiotherapy and chemotherapy \\ndrugs all the time. Biological therapies such as MABs, \\ncancer vaccines, and gene therapies are all active areas of \\nresearch. There are various anti-angiogenic drugs that can \\nstop cancers from growing the blood vessels that they need. \\nResearch is also looking into developing cost-effective ways \\nof screening for the different common cancers so they can \\nbe diagnosed early enough to be cured.', metadata={'source': 'data/cancer_and_cure__a_critical_analysis.27.pdf', 'page': 1}),\n",
       " Document(page_content='of screening for the different common cancers so they can \\nbe diagnosed early enough to be cured.\\nAvoiding immune destruction is now considered a hallmark \\nof cancer, and the immunotherapy arena has exploded \\nwith the recent advances demonstrating an improvement \\nin survival and a durability of response in patients with \\ndifferent cancer types, like in melanoma, which translates \\ninto an improved overall survival benefit.[5] To name those \\nimmunotherapeutic strategies that include the adoptive \\ntransfer of ex vivo activated T cells, immunomodulatory \\nMABs, and cancer vaccines. Advances in molecular \\npathology will provide the means to identify the targets \\nand will be used to subtype tumors and will provide predict \\nresponse to therapy and provide prognostic information.[6]\\nConclusion\\nUnfortunately , although we do fairly well  (and in some cases \\nvery well) against early stage cancer, we do not do so well \\nagainst Stage IV metastatic disease, particularly solid tumors.', metadata={'source': 'data/cancer_and_cure__a_critical_analysis.27.pdf', 'page': 1}),\n",
       " Document(page_content='against Stage IV metastatic disease, particularly solid tumors. \\nThere is still a long way to go before we can cure most cancers.\\nFinancial support and sponsorship\\nNil.\\nConﬂicts of interest\\nThere are no conflicts of interest.\\nReferences\\n1. Mackay J, Jemal A, Lee NC, Parkin DM. The Cancer Atlas. Atlanta: \\nAmerican Cancer Society; 2006.\\n2. Hanahan D, Weinberg RA. Hallmarks of cancer: The next generation. Cell \\n2011;144:646-74.\\n3. Reeves GK, Beral V, Green J, Gathani T, Bull D; Million Women Study \\nCollaborators. Hormonal therapy for menopause and breast -cancer risk \\nby histological type: A cohort study and meta -analysis. Lancet Oncol \\n2006;7:910-8.\\n4. Cuzick J, DeCensi A, Arun B, Brown PH, Castiglione M, Dunn B, et al.  \\nPreventive therapy for breast cancer: A consensus statement. Lancet \\nOncol 2011;12:496-503.\\n5. Couzin -Frankel J. Breakthrough of the year 2013. Cancer immunotherapy. \\nScience 2013;342:1432-3.\\n6. Bennett WP, Hussain SP, Vahakangas KH, Khan MA, Shields PG,', metadata={'source': 'data/cancer_and_cure__a_critical_analysis.27.pdf', 'page': 1}),\n",
       " Document(page_content='Science 2013;342:1432-3.\\n6. Bennett WP, Hussain SP, Vahakangas KH, Khan MA, Shields PG, \\nHarris CC. Molecular epidemiology of human cancer risk: Gene -environment \\ninteractions and p53 mutation spectrum in human lung cancer. J Pathol \\n1999;187:8-18.\\nDownloaded from http://journals.lww.com/indianjcancer by BhDMf5ePHKav1zEoum1tQfN4a+kJLhEZgbsIHo4XMi0\\nhCywCX1AWnYQp/IlQrHD3i3D0OdRyi7TvSFl4Cf3VC1y0abggQZXdgGj2MwlZLeI= on 12/03/2023', metadata={'source': 'data/cancer_and_cure__a_critical_analysis.27.pdf', 'page': 1}),\n",
       " Document(page_content='Abhishek Joshi  \\nCorinne Ryan  \\nSabe Sabesan  \\nSuresh Varma  \\nZulfiquer Otty  \\n \\n \\nDEPARTMENT OF MEDICAL ONCOLOGY  \\nTOWNSVILLE CANCER CENTRE  \\nTOWNSVILLE UNIVERSITY HOSPITAL  \\nTOWNSVILLE , AUSTRALIA  \\n \\n  \\n \\n \\n \\n \\n \\n \\n \\nMEDICAL ONCOLOGY HANDBOOK  \\nFOR JUNIOR MEDICAL OFFICERS', metadata={'source': 'data/medical_oncology_handbook_june_2020_edition.pdf', 'page': 0}),\n",
       " Document(page_content='Medical Oncology Handbook for Junior Medical Officers  \\n5th Edition June 2020, \\nTownsville, Australia.  \\n \\nTownsville Cancer Centre is a teaching partner of the James Cook University and \\nresearch partner of the Australian Institute of Tropical Health &Medicine,  \\nTownsville, Queensland, Australia .', metadata={'source': 'data/medical_oncology_handbook_june_2020_edition.pdf', 'page': 1}),\n",
       " Document(page_content='1 \\n  \\nINTRODUCTION:  \\nWelcome to the Department o f Medical Oncology at the Townsville Cancer Centre. By \\nthe end of the term, you should be able to identify and manage common side effects of \\nchemotherapy and radiotherapy in the areas  of general practice, emergency departments \\nand rural hospitals and general medical wards. Y ou will also have some understanding of \\ntreatment principles and aims of cancer therapy for common malignancies. This \\nhandbook is meant for the use of resident medical officers and basic physician trainees. \\nIt may also be useful to advanced trainees in the ir first few months of training. We hope \\nthat this experience will give you the skills to deal with cancer patients with positive and \\nempathetic approach.  \\nIf you are encountering emotional difficulties when dealing with poor prognosis, please \\ntalk to one o f us earlier in the term to learn ways to deal with it effectively.  \\n \\nEnjoy the medical oncology rotation.  \\n \\n \\nRegards,', metadata={'source': 'data/medical_oncology_handbook_june_2020_edition.pdf', 'page': 2}),\n",
       " Document(page_content='Enjoy the medical oncology rotation.  \\n \\n \\nRegards,  \\n \\nCONSULTANT MEDICAL ONCOLOGISTS', metadata={'source': 'data/medical_oncology_handbook_june_2020_edition.pdf', 'page': 2}),\n",
       " Document(page_content='2 \\n TABLE OF CONTENTS   \\nORIENTATION TO MEDIC AL ONCOLOGY DEPARTME NT ............................  3 \\nPRINCIPLES OF MANAGE MENT OF PATIENTS ON SYSTEMIC THERAPY  9 \\nCommon side effects of systemic therapeutic agents  ................................ ................  13 \\nChemotherapy related emesis  ................................ ................................ ....................  16 \\nPRINCIPLES OF TARGET ED THERAPY  ................................ ..............................  19 \\nPRINCIPLES OF CANCER  IMMUNOTHERAPY  ................................ .................  21 \\nMedical Oncology Emergencies  ................................ ................................ ................  32 \\nSUMMARY OF MANAGEMEN T OF COMMON CANCERS   ............................  33 \\nBREAST CANCER  ................................ ................................ ................................ .... 33', metadata={'source': 'data/medical_oncology_handbook_june_2020_edition.pdf', 'page': 3}),\n",
       " Document(page_content='Cancers of the Gas tro-Intestinal Tract  ................................ ................................ ..... 37 \\nGBM  ................................ ................................ ................................ ...........................  41 \\nGERM CELL TUMOURS  ................................ ................................ .........................  41 \\nHEAD AND NECK CANCER  ................................ ................................ ...................  43 \\nLUNG CANCER  ................................ ................................ ................................ ........  43 \\nMELANOMA  ................................ ................................ ................................ .............  45 \\nGYNAECOLOGICAL CANCER  ................................ ................................ ...............  47 \\nCANCERS OF GENITO URINAR Y SYSTEM  ................................ ........................  48', metadata={'source': 'data/medical_oncology_handbook_june_2020_edition.pdf', 'page': 3}),\n",
       " Document(page_content='3 \\n ORIENTATION TO MEDICAL ONCOLOGY DEPARTMENT  \\nJunior medical officers play an important role in the day-to-day care of patients in \\nMedical Oncology Department . It is critical that you work in c lose collaboration with \\nsenior medical, nursing and allied health staff , along with our administrative support \\nofficers.  \\nWe have outlined some useful practice poi nts will help you to settle into our department \\nsmoothly.  \\nEducational and training resources  \\nElectronic medical records  \\nTownsville Cancer Centre uses MOSAIQ as its EMR. Please become familiar with \\nMOSAIQ by contacting the CNC for MOSAIQ on 32888 or through  our administrative \\nsupport officers 44331671 prior to commencement. We assume that you are familiar with \\nthe ieMR, the THHS -wide EMR.  \\nChemotherapy protocol  \\neviQ is a very useful website to learn chemotherapy protocols and side -effects. It also \\ncontains in formati on about managing extravasation (www.eviq.org.au ).', metadata={'source': 'data/medical_oncology_handbook_june_2020_edition.pdf', 'page': 4}),\n",
       " Document(page_content='contains in formati on about managing extravasation (www.eviq.org.au ). \\nNB: RMOs and interns are not expected to write chemotherapy orders. When \\nwriting oral chemotherapy, targeted agents and colony stimulating factors, please \\nexercise caution and follow the advice of your registrars and consultants.  \\nMedication prescribing  \\nQuality of inpatient medication prescribing can be improved by adhering to the THHS \\nguide for inpatient medication prescription . \\nEnd of life care bedside tutorial and introduction to telehealth  \\nThese two topics are available on YouTube  (searchable using the titles)  and are useful \\nresources for developing mental frameworks for approaching these topics.  \\nBasic principles of oncology  \\nClinical oncology for medical students is a useful resource for learning basic principles \\nof oncology care.  \\n \\nhttp://wiki.cancer.org.au/oncologyformedicalstudents/Clinical_Oncology_for_Medical_\\nStudents', metadata={'source': 'data/medical_oncology_handbook_june_2020_edition.pdf', 'page': 4}),\n",
       " Document(page_content='4 \\n Documentation  \\nSince funding for operations of medical departments are linked  to their clinical activities, \\nit is important to use coding terminologies during documentation  of patient notes . \\nIssues with central venous access devices  \\nWe use central lines commonly in oncology and therefore, it is prudent to be aware of \\nmanaging comp lications. As a rule , when it is difficult to draw blood from lines or inject \\nfluids, it is important to use imaging (including chest -Xray and linogram) for checking \\nthe position and viability before using the lines. Please seek advice when infection and \\nthrombosis are  suspected /proven . We can rarely save lines using antibiotics   \\nSelf-care  \\nPlease maintain physical, emotional, mental and spiritual health. Take  regular  breaks  as \\nmuch as possible and maintain effective work -life balance  (This doesn’t mean work is \\nbad and life is good; it is about having a balance that suits your needs) . Please seek help', metadata={'source': 'data/medical_oncology_handbook_june_2020_edition.pdf', 'page': 5}),\n",
       " Document(page_content='bad and life is good; it is about having a balance that suits your needs) . Please seek help \\nif you think you need help including emotional support and guidance.  \\nDay unit  \\n• Orientate with the Day -unit staff and introduce yourself t o senior nursing \\nstaff and establish working relationships  with them .   \\n• You are the first point of call for any issues in day unit and therefore, please \\nmake sure that you are always available during rostered hours.  Day unit relies \\non effective discharge o f patients to maintain flow. A delay due to one issue \\ncould delay the whole day’s operation and care of other patients.  \\n• Infusion reactions are medical emergencies: You should always attend to a \\npatient having a reaction, leaving everything else. If you are  not available, \\nplease make sure another doctor can attend the patient immediately.  \\nClinics  \\n• Being “On Time” is important! Clinics start on time so that patients can \\nreceive their chemotherapy in day unit without delays.', metadata={'source': 'data/medical_oncology_handbook_june_2020_edition.pdf', 'page': 5}),\n",
       " Document(page_content='receive their chemotherapy in day unit without delays.  \\n• If a patient is seen by the consulta nt in clinic, please ask them to sign the blue \\nform.  \\nDealing with consultants and registrars  \\nPlease don’t hesitate to seek help from senior medical staff. All changes in management \\nshould be discussed. Harass them even if they are busy!', metadata={'source': 'data/medical_oncology_handbook_june_2020_edition.pdf', 'page': 5}),\n",
       " Document(page_content='5 \\n Dealing with nurses and other health professionals  \\n• Advice from nursing staff is an important resource for patient care.  \\n• When chemotherapy changes, delays or cancellation occur, it is prudent to \\ninform the nursing and pharmacy staff. \\nDealing with patients on chemothera py and chemotherapy orders  \\n• When you see a patient for chemotherapy review, please prepare the care \\nplans for the next cycle.  \\n• Dose reduction: After consultation with senior medical staff, please document \\ndose reductions and make changes on MOSAIQ scripts. I f there is  a dose \\nincrease, it is possible only from the next cycle.  \\n• All chemotherapy booking s are done through administration officers and day \\nunit schedulers . \\n• Initial c hemotherapy orders should be counter -signed by a consultant.  \\n• Please be familiar with i mportant practice points for common medications as \\ndescribed in this hand book.  \\nAdmitted patients', metadata={'source': 'data/medical_oncology_handbook_june_2020_edition.pdf', 'page': 6}),\n",
       " Document(page_content='described in this hand book.  \\nAdmitted patients  \\n• Make sure they are seen by consultants within 24 hours of admission and on a \\nregular basis;  \\n• Have an expected date of discharge and do the discharge planning , including \\ntimely completion of high -quality discharge summaries; ideally on the day \\nof discharge, using the national guide for discharge summaries . \\n• If a patient undergoing chemotherapy is admitted with complications, inform \\nthe day -unit and the treating consultant of any changes in treatment. It will \\nalso be important to document this episode on MOSAIQ for continuity of \\ncare and future planning includ ing dose changes and addition of GCSF.  \\n• If any oncology patient is admitted in another department or another hospital \\nwith complications, inform the treating consultant and document on \\nMOSAIQ.  \\n• In-patient consults from other departments need to be seen on th e same day, \\ndiscussed with or seen by the consultant on call and documented on \\nMOSAIQ.', metadata={'source': 'data/medical_oncology_handbook_june_2020_edition.pdf', 'page': 6}),\n",
       " Document(page_content='discussed with or seen by the consultant on call and documented on \\nMOSAIQ.  \\n• It is important to i nform the consultant on call of any patients admitted to \\nmedical oncology.  \\nRemember to use telehealth for appointments via our teleoncology coordinator. Telehealth is \\nappropriate for  most rural &  selected metro patients', metadata={'source': 'data/medical_oncology_handbook_june_2020_edition.pdf', 'page': 6}),\n",
       " Document(page_content='6 \\n  \\nCONSULTANT MEDICAL O NCOLOGISTS/ SENIOR M EDICAL \\nOFFICERS  \\nProfessor Sabe  Sabesan  \\nBMBS (Flinders) , PhD, FRACP  \\nSenior  Staff Specialist  \\nClinical Dean, James Cook University &  \\nTownville Hospital and Health Services  \\n \\nDr Suresh Varma  \\nMBBS , MD, DM, FRACP  \\nSenior Staff Specialist and senior lecturer  \\n \\nDr Abhishek Joshi  \\nMBBS,  MD, DM, FRACP  \\nSenior Staff Specialist and senior lecturer  \\n \\nDr Zulfiquer Otty  \\nMBBS, MD, MRCP, FRACP  \\nStaff specia list and senior lecturer  \\n \\nDr Corinne Ryan  \\nMBBS (Hons), B  Appl  Sci, FRACP  \\nStaff specialist and senior lecturer  \\n \\nDr Christine Mitchell  \\nMBBS (Adelaide), FRACGP  \\nSenior Medical Officer Medical Oncology', metadata={'source': 'data/medical_oncology_handbook_june_2020_edition.pdf', 'page': 7}),\n",
       " Document(page_content='7 \\n WEEKLY TIMETABLE  \\nTime  Mon day Tues day Wed nesday  Thurs day Friday \\n0745 -0830  GI MDT  \\n(0800 -0900)   Breast MDT  \\nGynae MDT \\nevery three \\nweeks  \\n  Colorectal  \\nMDT  \\n(0800 -0900)  \\n0900 -1200  Clinics  \\nSV, ZO, \\nCR Clinic  \\nSV, ZO \\nH&N MDT  Clinic  \\nCM, SV,  AJ Clinic  \\nCM, CR, AJ, \\nZO Clinic  \\nSV, ZO, AJ, \\n1230 -1330  Grand rounds  \\n(RDA)  Clinic  \\nSS \\n Radiology  \\n(Weekly) /  \\nUro MDT \\n(fortnightly)  Clinical \\nReasoning  \\n(RDA)   \\n1330 - Clinic \\nSpill -over Clinic  \\nAJ/SV  Skin MDT  \\n(1300 -1400)   \\n1400 -1500  Journal Club  \\nReg training \\nM&M   \\n1500 -1600  \\n1600 -1700   Neuro -MDT \\n(monthly ) Lung MDT   \\nEducational aims for this rotation:  \\n• Management of complications of systemic therapy . \\n• Familiarity with common systemic therapy  regimens . \\n• Management of medical emergencies . \\n• Management of quality of life issues . \\n• Understanding of psychosocial issues related to cancer patients - discussing  \\nprognosis, breaking bad news, family meetings etc.', metadata={'source': 'data/medical_oncology_handbook_june_2020_edition.pdf', 'page': 8}),\n",
       " Document(page_content='prognosis, breaking bad news, family meetings etc. \\n• Understanding of curative vs palliative intent therapy . \\n• Familiarity  with the management of common maligna ncies including \\nmultidisciplinary approach . \\n 1430 -1530  \\nLong case \\npractice for \\nBPT, RMO \\nand Interns', metadata={'source': 'data/medical_oncology_handbook_june_2020_edition.pdf', 'page': 8}),\n",
       " Document(page_content='8 \\n Routine t asks:  \\n• Managing inpatients – routine inpatient care, ward consultations, weekend \\nroster (it is the responsibility of the registrars to do this roster).  \\no Prior to consultant ward rounds, results should be available for imaging \\nstudies, histology and blood tests.  \\no (For interns, all the procedures except IV cannulation need to be initially \\nsupervised by registrars or consultants).  \\n• Review of day unit patients . \\n• Review of clinic patients . \\n• Phone consults  from GPs, other staff and the patients . \\n• Participation in a long case practice session each Tuesdays (taking turn \\namong BPT, RMO and Interns)  and other education sessions listed in the \\ntime- table  \\n• Participation in departmental Research and/or Quality Impro vement projects  \\n \\nDay unit and clinic patient review:  \\n• To assess fitness for systemic therapy . \\n• To assess symptoms and side effects of treatment.  \\n• To address new concerns .  \\n• To assess for treatment response -', metadata={'source': 'data/medical_oncology_handbook_june_2020_edition.pdf', 'page': 9}),\n",
       " Document(page_content='• To address new concerns .  \\n• To assess for treatment response -  \\no tumour markers , \\no scans - performed after 2 -3 cycles .    \\n• To update systemic therapy  scripts .', metadata={'source': 'data/medical_oncology_handbook_june_2020_edition.pdf', 'page': 9}),\n",
       " Document(page_content='9 \\n PRINCIPLES OF MANAGE MENT OF PATIENTS ON \\nSYSTEMIC THERAPY  \\nAssessing fitness for systemic therapy  \\nFitness for systemic therapy  depends on many  factors:  \\n• performance status , \\n• the type and severity of side effects from pr evious cycles or doses , \\n• blood parameters , \\n• co-morbidities  and \\n• Patient choice  \\nIf cure is the aim, it is usual to accept mild -to-moderate, non -life-threatening toxicities \\nand continue treatment without delaying or reducing the dosage to minimise side effects. \\nSometimes it is prudent to use supportive therapy such as  G-CSF to maintain  dose \\nintensity. However, in patients with incurable metastatic disease where quality of life is \\nparamount, dose delays or dose reductions are necessary.  \\nPerformance status  \\nThis is graded using the Eastern Cooperative Oncology Group (ECOG) scale.  \\n \\nGrade  ECOG performance status  \\n0 Fully active, able to carry on all pre -disease performance without \\nrestriction .', metadata={'source': 'data/medical_oncology_handbook_june_2020_edition.pdf', 'page': 10}),\n",
       " Document(page_content='0 Fully active, able to carry on all pre -disease performance without \\nrestriction . \\n1 Restricted in physically strenuous activity but ambulatory and able to \\ncarry out work of a light or sedentary nature, e.g., light house work, \\noffice work  \\n2 Ambulatory and capable of all selfcare but unable to carry out any \\nwork activities. Up and about more than 50% of waking hours  \\n3 Capable of only limited selfcare, confined to bed or chair more than \\n50% of waking hours  \\n4 Completely disabled , cannot carry on any self -care, totally confined \\nto bed or chair  \\n \\nUsually, patients with ECOG grade > 2 are not fit for chemotherapy. The exception is \\nchemotherapy -sensitive cancers such as lymphoma and small cell lung cancers. The \\ndecision to offer chemotherapy must be individualised , depending upon factors such as  \\nage of the patient, & comorbidities.  For example, a young patient with metastatic breast', metadata={'source': 'data/medical_oncology_handbook_june_2020_edition.pdf', 'page': 10}),\n",
       " Document(page_content='10 \\n cancer with poor performance status could still be offered systemic treatments. Targeted \\nagents and  endocrine therapy are usually tolerated better than chemotherapy.  \\n \\nToxicity from previous cycles of systemic therapy  \\nClinicians must assess whether a side effect is affecting QOL, performance status  or is \\nlife threatening:  \\nFirst, determine the type and se verity of side effects.  \\nFor example, in patients with early breast cancers undergoing taxane chemotherapy, mild \\nperipheral neuropathy is acceptable. However, in patients undergoing fluorouracil -based \\ntherapy, ongoing or severe diarrhoea necessitates a dose  delay and dose reduction of \\nsubsequent cycles.  \\nMid-cycle neutropenic fever usually requires dose reduction of the subsequent cycle \\nunless the cancer is curable. If the cancer is curable or a substantial duration of remission \\nis expected, prophylactic colo ny stimulating factors such as pegfilgrastim (neulasta)', metadata={'source': 'data/medical_oncology_handbook_june_2020_edition.pdf', 'page': 11}),\n",
       " Document(page_content='is expected, prophylactic colo ny stimulating factors such as pegfilgrastim (neulasta) \\nand/or antibiotics can reduce the risk of subsequent and opportunistic infection s. \\n \\nNext, determine the effects on important organs, such as:  \\n• Fertility. Discuss semen cryopreservation with men. Option s for women \\nshould also be discussed, particularly in young women of child -bearing \\npotential and where curative intention treatment is planned.  Options include  \\npreservation of egg, embryo and a piece of ovary is offered by some fertility \\ngroups. Women who  wish to discuss this option should be referred to a \\nfertility specialist.  \\n• Renal function, liver functions.  \\n• Cardiac function. This may affect the dosage of anthracyclines (check \\nejection fraction before treatment begins and after every 2 –3 cycles) and \\ntrastuzumab (check ejection fraction before treatment begins and every 3 \\nmonths during therapy).', metadata={'source': 'data/medical_oncology_handbook_june_2020_edition.pdf', 'page': 11}),\n",
       " Document(page_content='trastuzumab (check ejection fraction before treatment begins and every 3 \\nmonths during therapy).  \\nToxicity is graded according to NCI common terminolo gy criteria for adverse events1. \\n1. Blood parameters:  \\na. Requires haematological and non-haematological parameters.  \\n \\n1 National cancer institute common toxicity criteria (CTCAE, version 4.03, June \\n2010 ), National Institutes of Health, National Cancer Institute  . \\nhttp://ctep.cancer.gov .', metadata={'source': 'data/medical_oncology_handbook_june_2020_edition.pdf', 'page': 11}),\n",
       " Document(page_content='11 \\n For most regimens, a neutrophil count >1.5 x 109/L and platelet count > 100 x \\n109/L are needed for safe administration of chemotherapy. For some regimens, \\nlower levels may be acceptable.  \\nSingle agent bleomycin and vincristine  are not myelotoxic and administration is \\nnot affected by blood counts.  \\nRenal function is important for cisplatin and carboplatin and liver function for \\ndocetaxel , Magnesium levels especially  for cisplatin  and Calcium levels for \\ndenosumab.  \\nAction  - withhold treatment until recovery, then dose delay and/or dose reduction  \\nafter discussion with senior staff . \\nb. Pregnancy test: For women of child bearing potential, perform beta HCG \\nbefore initiating treatment.  \\n2. Non-haematological toxicity  \\n(Also see the summa ry of common side effects for selected drugs on page 25). \\na. Diarrhoea – mainly 5FU based, Irinotecan, Oxaliplatin, docetaxel . \\nAction  - low threshold for withholding therapy if diarrhoea the day before , or', metadata={'source': 'data/medical_oncology_handbook_june_2020_edition.pdf', 'page': 12}),\n",
       " Document(page_content='Action  - low threshold for withholding therapy if diarrhoea the day before , or \\nmoderate diarrhoea for longer than expected duration , or nocturnal diarrhoea.  \\nb. Mucositis/mouth care . \\nc. Emesis . \\n   Action  - (see anti -emetics) change class, change route, add another agent , or  \\n   reduction of chemotherapy dose.  \\nd. Skin Rash . \\ne. Neuropathy - Cisplatin, Oxaliplatin, Taxanes and Vinca alkaloids . \\n               Doses are delayed , reduced or omitted if neuropathy persists or interferes with  \\n               function.  \\nf. Autotoxicity - Cisplatin . \\ng. Renal impairment - Cisplatin.  \\nAction - prior to most agents, need to check creatinine especially if they are renally \\ncleared  and Carboplatin  dose adjusted based on creatinine.  \\nh. Pulmonary toxicity - bleomycin, methotrexate . \\n3. Physical  examination -Routine exam and oral cavity, central lines and IV site \\ninfections, lymph nodes and signs of recurrence and side effects.', metadata={'source': 'data/medical_oncology_handbook_june_2020_edition.pdf', 'page': 12}),\n",
       " Document(page_content='12 \\n Symptom control  \\nDiscussion or shared care with palliative care is helpful.  However, basic principles are as \\nfollow s: \\n(Also refer to the Guide for inp atient medication prescription)  \\n1. Pain:    Always find out the cause of the pain before prescribing analgesics . \\nTotal daily morphine requirement will guide the required daily slow release dose. \\nWhen prescribing breakthrough, the dose is 1/6th of the daily do se. So, if you are \\nincreasing the daily dose, break through need s to increase as well. If oral intake is \\ndifficult —patches or infusional morphine are options.  \\n4. Dyspnoea:    Again, find out the cause, for cancer related dyspnoea —nebulised \\nmorphine and anxioly tics could be helpful.  \\nWhen to stop cancer treatment  \\nA decision to stop treatment prematurely depends on the aim of the treatment.  \\nFor curable cancers, it is acceptable to continue treatment with dose modifications.', metadata={'source': 'data/medical_oncology_handbook_june_2020_edition.pdf', 'page': 13}),\n",
       " Document(page_content='For curable cancers, it is acceptable to continue treatment with dose modifications. \\nHowever, life threatening or severe dose  limiting toxicities usually necessitate cessation \\nof treatment (eg. moderate to severe peripheral neuropathy with taxanes and oxaliplatin, \\nsevere enteritis from fluorouracil). Alternative regimens are sometimes available.  \\nIf the cancer is incurable and th e toxicities severely interfere with the activities of daily \\nliving, treatment may have to be stopped.  \\nDeteriorating performance status and organ function usually require cessation of \\ntreatment. Ongoing neutropenia or thrombocytopenia typically means the p atient is not \\ngoing to handle further chemotherapy.  \\nIn case of patients with metastatic disease, palliative care team referral is done even when \\nthey are on active treatment, to improve symptom management and supportive care.', metadata={'source': 'data/medical_oncology_handbook_june_2020_edition.pdf', 'page': 13}),\n",
       " Document(page_content='13 \\n Common side effects of systemic therapeutic agents  \\n• Adriamycin/ Epirubicin    \\nBe aware of cumulative dose, p erform cardiac function every 2-3cycles.  \\n• Bleomycin -  \\nLung functions every 3 weeks  (consider, discuss with consultant)  \\n• Cisplatin  \\nRenal function, Mg levels, peripheral neuropathy, hearing loss/tinnitus.  \\n• Carboplatin  \\nAdjust dose based on renal function; Dose  = AUC x (GFR+25).  \\n• 5-FU \\nDiarrhoea -In severe cases, it can be life threatening.  \\nBefore proceeding with treatment, please make sure no diarrhoea on the day an d \\non the previous day of chemotherapy. When diarrhoea has been moderate to \\nsevere, consider dose reduction or cessation.  \\n5FU could also cause coronary artery spasm.  \\nIn severe 5FU enteritis, admission for bowel rest +/ -TPN along with \\naggressive anti diarrh oeal and antibiotics may be required.  \\n• Gemcitabine  \\nPneumonitis, peripheral edema.  \\n• Irinotecan - Normal bilirubin is required.', metadata={'source': 'data/medical_oncology_handbook_june_2020_edition.pdf', 'page': 14}),\n",
       " Document(page_content='• Gemcitabine  \\nPneumonitis, peripheral edema.  \\n• Irinotecan - Normal bilirubin is required.  \\nDiarrhoea and flushing: acute symptoms related to parasympathetic system could \\nsettle with atropine with chemotherapy.   \\nFor chron ic symptoms, dose reduction may necessary.  \\n• Taxol/ Paclitaxel  \\nPeripheral neuropathy, flu like symptoms .', metadata={'source': 'data/medical_oncology_handbook_june_2020_edition.pdf', 'page': 14}),\n",
       " Document(page_content='14 \\n • Taxotere/Docetaxel  \\nAdequate liver function, peripheral edema, neuropathy, rash.  \\n• Oxaliplatin  \\nCold induced paresthesia ( acceptable), but signs of peripher al Neuropathy may be \\ndose limiting.  Laryngo spasm (cold induced) and bronchospasm are other acute \\nside effects.  \\n• Cyclophosphamide/ Ifosfamide  \\nRenal function, hydration, confusion from encephalopathy.  \\n• Capecitabine  \\nMucositis, hand foot syndrome, rash, angina , diarrhoea.  \\n• Trastuzumab  \\nCardiac function every 3 months.  \\n• Cetuximab/Panitumumab  \\nAcneform rash.   \\n• Methotrexate  \\nFolinic acid rescue  for higher doses only . \\n• Caelyx/ Liposomal doxorubicin  \\nRash, hand foot syndrome, cardiac function.  \\n• Avastin /Bevacizumab  \\nHypertension and proteinuria.  \\n• Denosumab  \\nProlonged hypocalcaemia  (require calcium suppliments).  \\n• Dabrafenib  (b-Raf inhibitor)  \\nPyrexia, rash, s quamous cell carcinomas of skin.  \\n• Mekinist – MEK inhibitor', metadata={'source': 'data/medical_oncology_handbook_june_2020_edition.pdf', 'page': 15}),\n",
       " Document(page_content='Pyrexia, rash, s quamous cell carcinomas of skin.  \\n• Mekinist – MEK inhibitor  \\nUsually  combined with Dabrafenib to reduce in cidence of skin squamous cell \\ncarcinoma  \\n• Zolendronic acid  \\nRenal function, hypocalcaemia, requires dose reduction for renal impairment.  \\nNeed calcium supplements .', metadata={'source': 'data/medical_oncology_handbook_june_2020_edition.pdf', 'page': 15}),\n",
       " Document(page_content='15 \\n • Check point inh ibitors (Ipilumumab, nivolumab , Pembrolizumab ) \\nAutoimmune complications such as  colitis, pneumonitis, hepatitis and \\ninflammation  of pituitary gland leading to Addison’s crisis require urgent medical \\nattention.  \\n• Alopecia  \\nThis does not occur with every medication.  \\nCommon with breast, ovarian, sarcoma, small cell, lung (Carbo/Taxol) canc er and \\ntesticular regimens  \\nCommon chemotherapy abbreviations  \\nBreast Cancer   \\nTAC  Docetaxel, Adriamycin, Cyclophosphamide  \\nFEC  5Fluorouracil, Epirubicin, Cyclophosphamide  \\nAC (inc DD) Adriamycin, Cyclophosphamide (DD for dose dense)  \\nTC Docetaxel, Cyclophosphamide  \\nColo -rectal Cancer   \\nFOLFOX  Oxaliplatin, Continious infusion 5Fluorouracil and \\nLeucovorin  \\nXELOX  Oxaliplatin, Capecitabine  \\nFOLFIRI  Irinotecan, Continious infusion 5 Fluorouracil and \\nLeucovirin  \\nXELIRI  Irinotecan, Capecitabine  \\nGastric/Lower Oesophageal   \\nECF  Epirubicin, Cisplatin, 5 Fluorouracil', metadata={'source': 'data/medical_oncology_handbook_june_2020_edition.pdf', 'page': 16}),\n",
       " Document(page_content='Gastric/Lower Oesophageal   \\nECF  Epirubicin, Cisplatin, 5 Fluorouracil  \\nEOX Epirubicin, Oxaliplatin , Capecitabine  \\nFLOT  5FU, Leucovorin , Oxaliplatin, Docetaxel  \\nHead and Neck Cancer   \\nTPF  Docetaxel, Cisplatin, 5 Fluorouracil  \\nTesticular Cancer   \\nBEP  Bleomycin, Etoposide, Cisplatin  \\nTIP Paclitaxel, Ifosfamide, Cisplatin', metadata={'source': 'data/medical_oncology_handbook_june_2020_edition.pdf', 'page': 16}),\n",
       " Document(page_content='16 \\n Chemotherapy related emesis  \\nCauses of nausea and vomiting in patients receiving chemotherapy:  \\n• Chemotherapy related . \\n• Other causes such as  gastro -oesophageal reflux disease or medications \\nrelated.  \\nPathways by which chemotherapeutic agents may produce an emetic \\nresponse 2 \\n \\n \\nChemotherapy -induced emesis  results from stimulation of a multistep reflex pathway that \\nis controlled by the brain and triggered by afferent impulses to the vomiting centre  from \\nthe chemoreceptor trigger zone, gastrointestinal tract (by way of vagal affere nt fibres ), \\nand possibly, the cerebral cortex.   \\n \\n2 Hesketh, P. J. (2008). \"Chemotherapy -induced nausea and vomiting.\" New England \\nJournal of Medicine  358(23): 2482 -2494.', metadata={'source': 'data/medical_oncology_handbook_june_2020_edition.pdf', 'page': 17}),\n",
       " Document(page_content='17 \\n Emetogenic potential of chemotherapy agents  \\n \\nHigh  \\n(>90%)  Moderate  \\n(60-90%)  Moderate  \\n(30-60%)  Low  \\n(10-30%)  Minimal  \\nCisplatin \\n>50mg/m2  Carboplatin  Cyclophos \\n<750mg/m2  Xeloda/5FU  Bleomycin  \\nDacarbazine  \\n Cisplatin  \\n<50mg/m2  cabazitaxel  Docetaxel  Herceptin  \\nCyclophos>  \\n1.5g/m2  Doxorubicin  \\n>60mg/m2  Doxorubicin  \\n20-60mg/m2  Caelyx  Cetuximab  \\n Epirubicin  \\n>90mg/m2  Epirubicin \\n<90mg/m2  Taxol  Vincristine  \\n  Irinotecan,  \\nOxaliplatin  Gemzar,  Vinorelbine  \\n*Acute or early nausea and vomiting - within 24 hours of chemotherapy.  \\n*Delayed/late – after 24 hours of chemotherapy. .  \\nFor Cisplatin, emesis reaches its maximal intensity 48 -72 hours after chemotherapy and \\ncan last up  to 6-7 days.  \\n*Anticipatory nausea and vomiting - Nausea before chemotherapy  \\nFive neurotransmitter receptor sites are of primary importance in the vomiting reflex: M1 \\n– muscarinic, D2 – dopamine, H1 – histamine, 5 -hydroxytryptamine (HT) -3 – serotonin,', metadata={'source': 'data/medical_oncology_handbook_june_2020_edition.pdf', 'page': 18}),\n",
       " Document(page_content='– muscarinic, D2 – dopamine, H1 – histamine, 5 -hydroxytryptamine (HT) -3 – serotonin, \\nNeurokinin 1 (NK1) receptor – substance P  \\nAntiemetics  \\n• Neurokinin 1 receptor antagonist - Aprepitant (emend), fosaprepitant  \\n(Only for prophylaxis ). \\n• 5HT3 antagonists: ondansetron (zofran), granisetron & palonosetron  (aloxi) . \\n• Dopamine antagonists: 1.  Phenothiazines - prochlorperazine, 2. Benzamides: \\nMetoclopromide.  3.  Butyrophenons -haloperidol . \\n• Glucocorticoids: active in early and delayed nausea.  \\n• Anti-histamines: Promethazine . \\n• Benzodiazepins: Lorazepam (useful for anticipatory emesis) .', metadata={'source': 'data/medical_oncology_handbook_june_2020_edition.pdf', 'page': 18}),\n",
       " Document(page_content='18 \\n High emetogenic drugs and anthracycline containing regime ns for breast \\ncancer3  \\n• NK1 inhibitors: eg Emend (Aprepitant)  \\nDay 1: 165 mg pre chemotherapy with no subsequent doses . \\nPlus \\n• 5HT3 antagonists: eg Aloxi (Palonosetron)  250 mcg IV on  Day 1 only or \\nOndansetron 8mg twice daily for 2 -3 days starting the night of chemotherapy.  \\nPlus \\n• Dexamethasone  \\n8-12 mg IV pre -chemo and 8mg oral mane for 2 -3 days.  \\nNB- for patients who ex perience sudden decline in well -being when steroids are \\nstopped, a weaning off regimen might be useful.  \\n• Metoclopramide  \\n10 mg Q6H PRN.  \\nNB: 5HT antagonists can be constipating  - so warn patients about prevention of \\nconstipation. No need to prescribe take -home 5HT antagonists after Palonosetron.  \\nModerately emetogenic drugs or combination of drugs:  \\n• 5HT3 antagonist : eg Aloxi (Palonosetron)  250 mcg IV on day 1 Plus. \\n• Dexamethasone  8 mg IV pre -chemo and 8mg oral mane 2 -3 days .', metadata={'source': 'data/medical_oncology_handbook_june_2020_edition.pdf', 'page': 19}),\n",
       " Document(page_content='• Dexamethasone  8 mg IV pre -chemo and 8mg oral mane 2 -3 days . \\nNK1 inhibitors  can be added to the above regimen if the patients experience \\nnausea & vomiting after moderately emetogenic chemotherapy.  \\nMildly emetogenic drugs:  \\nUsually premedication with metoclopramide 10 mg Q6H PRN would be adequate. \\nIf nausea is not controlled, we may have to treat it like moderate drugs after \\nexcluding other causes of nausea such as gastroesophageal  reflux and \\nulcers/gastritis.  \\nIf nausea persi sts, consider other causes.  \\nAddition of lorazepam 1 mg Q6H PRN may be useful especially for anxious \\npatients . \\n \\n3 Roila, F., J. Herrstedt, et al. (2010). \"Guideline update for MASCC and ESMO in \\nthe prevention of chemotherapy - and radiotherapy -induced nausea and vomiting: \\nresults of the Perugi a consensus conference.\" Annals of Oncology  21 Suppl 5 : v232 -\\n243.', metadata={'source': 'data/medical_oncology_handbook_june_2020_edition.pdf', 'page': 19}),\n",
       " Document(page_content='19 \\n PRINCIPLES  OF TARGETED THERAPY   \\n  \\n \\nIf we use analogy of pesticides : empiric chemotherapy would be “Raid” while targeted \\ntherapy is “R oach Hotel”.   \\nDr David Gandara  \\nIt is like using a “smart”  bomb versus a “cluster” bomb.  \\nDr Nevin Murray  \\n \\nThe figure below d epicts typical targets for anti -cancer drugs which could be pathways, \\nprocesses and physiology which are uniquely dis rupted in cancer cells: receptors, genes, \\nangiogenesis, tumour pH etc.', metadata={'source': 'data/medical_oncology_handbook_june_2020_edition.pdf', 'page': 20}),\n",
       " Document(page_content='20 \\n  \\nTable 1 below depicts some targ ets and commonly available anti -cancer drugs in common \\nsolid tumours . \\n \\nTable 1 Targets and examples of treatments for common solid tumours.  \\nDisease  Target  Treatment  \\nAdenocarcinoma of lung  EGFR exon 9, 11 mutation  Erlotinib, Gefitinib , Afatinib  \\n T 790M  Osemertinib  \\n ALK -EML4 fusion gene  Crizotinib /Alectinib  \\nMelanoma  BRAF  Dabrafenib, Vemurafinib  \\n MEK  Mekinist  \\nColon Cancer  RAS  Cetuximab, Panitimumab  \\nBreast Cancer  Her 2 neu amplification  Trastuzumab , Pertuzumab, \\nLapatinib  \\n ER and PR  Tamoxifen, Aromatase \\nInhibitors  \\nProstate Cancer  AR receptor  Enzalutamide, Abiraterone  \\nGIST  CD 117 (c -kit) Imatinib Mesylate', metadata={'source': 'data/medical_oncology_handbook_june_2020_edition.pdf', 'page': 21}),\n",
       " Document(page_content='21 \\n PRINCIPLES OF CANCER  IMMUNOTHERAPY  \\n \\n \\n \\n(CTLA4 outcompetes CD28 for CD80 and CD86, and the costimulatory signal ceases as \\nthe target is eliminated, reducing the release of pro -effector cytokines such as IL -12 and \\ncytotoxic enzymes such as perforin and granzyme B. Homeostasis is restored.)  \\n \\nIn a state of chronic antigen presentation, such as malignancy, the chronic presence of \\nantigen or pro -inflammatory cytokines (IL -12, IFN  gamma, etc) can upregulate PD -1 \\nexpression on the T cell; tumour  clones can also select for PD -L1 expre ssion. With PD -\\n1-PD-L1 binding, even in the presence of the costimulatory molecule, \"peripheral \\nexhaustion\" can occur.  \\n \\n \\n \\n \\nThe anti -CTLA -4 antibody, ipilimumab  was the first immune checkpoint inhibitor to be \\napproved based upon its ability to prolong survival in patients with metastatic mel anoma.  \\nProgrammed cell death 1 (PD -1) is a trans -membrane protein expressed on T cells, B', metadata={'source': 'data/medical_oncology_handbook_june_2020_edition.pdf', 'page': 22}),\n",
       " Document(page_content='Programmed cell death 1 (PD -1) is a trans -membrane protein expressed on T cells, B \\ncells, and NK cells . It is an inhibitory molecule that binds to PD -ligand 1 (PD -L1; also \\nknown as B7 -H1) and PD -L2 (B7 -H2). PD -L1 is expressed on the surface of multiple \\ntissue types, including many tumour  cells, as well as hematopoietic cells; The IgG4 \\nsubclass PD -1 inhibiti ng antibodies  like nivolumab  and pembrolizumab  prolonged \\noverall survival in randomized trials in various cancers, including metastatic melanoma ,', metadata={'source': 'data/medical_oncology_handbook_june_2020_edition.pdf', 'page': 22}),\n",
       " Document(page_content='22 \\n clear cell renal carcinoma, bladder cancer, head and neck cancer  and non-small cell lung \\ncancer.  \\nImmune Response Criteria : The patt erns of response to treatment with these \\nimmunotherapy agents differ from those with molecularly -targeted agents or cytotoxic \\nchemotherapy in several important respects . \\nToxicities associated with checkpoint inhibitor immunotherapy  \\nCheckpoint inhibition is  associated with a unique spectrum of side effects termed \\nimmune -related adverse events (irAEs) or, occasionally, adv erse events of special \\ninterest . IrAEs include dermatologic, gastrointestinal, hepatic, endocrine, and other less \\ncommon inflammatory event s4. \\nIn general, treatment of moderate or severe irAEs requires interruption of the checkpoint \\ninhibitor and the use of corticosteroid immunosuppression. Treatment is based upon the \\nseverity of the observed toxicity:  \\n• For patients with grade 2 (moderate) imm une-mediated toxicities, treatment', metadata={'source': 'data/medical_oncology_handbook_june_2020_edition.pdf', 'page': 23}),\n",
       " Document(page_content='• For patients with grade 2 (moderate) imm une-mediated toxicities, treatment \\nwith the checkpoint inhibitor should be withheld and should not be resumed \\nuntil symptoms or toxicity is grade 1 or less. Corticosteroids should be started \\nif symptoms do not resolve quickly . \\n• For patients experiencing gra de 3 or 4 (severe or life -threatening) immune -\\nmediated toxicities, treatment with the checkpoint inhibitor should be \\npermanently discontinued. High doses of corticosteroids ( prednisone  1 to 2 \\nmg/kg/day or equivalent) should be given. When symptoms subside to grade \\n1 or less, steroids can be gradually tapered over at least one month.  \\n• Patients who will benefit from corticosteroids generally do s o within days. If \\nsymptoms do not clearly improve, particularly after approximately three days \\nwith intravenous steroids, our approach is to administer infliximab  (5 mg/kg) \\nrather than continue with a prolonged course of high -dose IV corticosteroids.', metadata={'source': 'data/medical_oncology_handbook_june_2020_edition.pdf', 'page': 23}),\n",
       " Document(page_content='rather than continue with a prolonged course of high -dose IV corticosteroids. \\nIf symptoms persist after the first infliximab dose, a second dose of \\ninfliximab (5 mg/kg) can be repeated two weeks after the initial dose.  \\n \\n \\nDetailed management of various toxicities is covered by Cancer Institute of NSW’s \\neviQ:Cancer Treatments Online site . Free registration is required for login.\\n \\n4 Naidoo J et al.(2015) Toxicities of the anti -PD-1 and anti -PD-L1 immune checkpoint \\nantibodies. Annals of Oncology 2015;26(12):2375', metadata={'source': 'data/medical_oncology_handbook_june_2020_edition.pdf', 'page': 23}),\n",
       " Document(page_content='23 \\n Common side effects of oncology medications  \\n Myelosuppression  Mucositis  Enteritis  Alopecia  Cardiac  Renal  Neuropathy  Liver  Rash  Lung \\nAnthracyclines  ++ +  ++ +   +   \\nCapecitabine  + ++ ++  angina     +HFS   \\nCarboplatin  ++      +    \\nCisplatin  +     ++ ++    \\nCyclophosphamide  +   +  +  +   \\n5FU  ++ ++  angina     +  \\nGemcitabine  +  +       + \\nIrinotecan  +  ++ +    +   \\nOxaliplatin   + + +    ++    \\nPaclitaxel  +   ++   ++    \\nDocetaxel  +  + ++   ++ + +  \\nPermetexed  +  +        \\n \\nExamples of Monoclonal antibodies and small molecules  \\n Infusion reactions  cardiac  rash  thyroid  Proteinuria  diarrhea  Hypertension  \\nTrastuzumab  + \\n+ \\n+ +      \\nBevaczuzumab     +  ++ \\nCetuximab/panitumab   ++     \\nSunitinib   ++ + + + +', metadata={'source': 'data/medical_oncology_handbook_june_2020_edition.pdf', 'page': 24}),\n",
       " Document(page_content='24 \\n FEBRILE NEUTROPENIA  \\nNeutropenic Fever 5 6 \\nIt is a medical emergency. It is the responsibility of the MO to ensure prompt \\nantibiotic administration.  \\nWith diarrhoea and neutropenia, even if afebrile, it is advisable to use the \\nsame protocol.  \\nDefinitions  \\n• A single oral temperature of 38.3  C.  \\n• A temperature ≥ 38  C on two occasions over 1 hour . \\n• ANC ≤ 500 or less ≤ 1000/µl with predicted rapid decline to less than 500/µl . \\nSeptic Work -Up \\n• Physical examination . \\n• Blood cultures x 2 sets (venipuncture and indwelling venous catheter if \\npresent), urine C&S, cultures from any  suspected sites, CXR ). \\nTreatment of Neutropenic Fever 7 \\nAntibiotics (early involvement of anti -microbial stewardship service is  \\nbeneficial) . \\n• Anti pseudomonal penicillins (Piperacillin/tazobactam & Ticarcillin) and \\ncephalosporins (Cefepime) are used as single agents.  \\nIn patients with hypersensitivity to pen icillins, seek expert advice.   \\nModifications', metadata={'source': 'data/medical_oncology_handbook_june_2020_edition.pdf', 'page': 25}),\n",
       " Document(page_content='In patients with hypersensitivity to pen icillins, seek expert advice.   \\nModifications  \\n• Aminoglycosides may be added  if patient is unstable to cover resistant \\npseudomonal bacteremia.  \\n \\n5 Freifeld, A. G., E. J. Bow, et al. (2011). \"Clinical practice guideline for the use of \\nantimicrobial agents in neutropenic  patients with cancer: 2010 Update by the \\nInfectious Diseases Society of America.\" Clinical Infectious Diseases 52(4): 427 -\\n431. \\n6 National Comprehensive Cancer Network (NCCN) Clinical P ractice Guidelines in \\nOncology, Prevention and treatmen t of cancer -related infections, Version 2.2011.  \\nwww.nccn.org  . \\n7 Therapeutic guidelines. online -tg-org-au.cknservices.dotsec.com', metadata={'source': 'data/medical_oncology_handbook_june_2020_edition.pdf', 'page': 25}),\n",
       " Document(page_content='25 \\n • Add Vancomycin if clinically unstable, gram positive blood cultures before \\nantibiotics, severe mucositis present, already on Quinolone prophylaxis, a \\ncatheter associated cellulitis or tunnel  infection, past history, high prevalence \\nor carrier of Methicillin -resistant staph aureus.  \\n• Metronidazole for abdominal symptoms or suspected C. difficile infection.  \\n• Persistent neutropenic fever on D5 – add antifungal therapy (Amphotericin B \\n0.5mg/kg /day o r Fluconazole 400mg/day) . \\nDiscuss with consultants first.  \\nDuration of Antibiotics (variable)  \\n• Low risk patient (clinically well, stable signs, no mucositis, ANC >100/µL, \\nrising ANC, afebrile within 2 -3 days of starting antibiotics, negative cultures) \\nconsid er early discharge on oral Ciprofloxacin and Augmentin for 5 days or \\ncease antibiotics altogether when ANC >500/µL . \\n• High risk patients,  who become afebrile within 3 days, should continue', metadata={'source': 'data/medical_oncology_handbook_june_2020_edition.pdf', 'page': 26}),\n",
       " Document(page_content='• High risk patients,  who become afebrile within 3 days, should continue \\nparenteral antibiotics, targeted to the specific pathogen, until reso lution of \\nneutropenia .  \\n• Specific pathogens need to be treated according to therapeutic guidelines \\nwhile continuing broad coverage.', metadata={'source': 'data/medical_oncology_handbook_june_2020_edition.pdf', 'page': 26}),\n",
       " Document(page_content='26 \\n Patients with any of the following characteristics are considered to be  at \\nhigh risk for serious complications during episodes of neutropenic fever  \\n• Neutropenia (absolute neutrophil count <500 cells/microL) anticipated to last \\n>7 days*   \\nPresence of any comorbid medical problems, including, but not limited to:  \\n• Hemodynamic instability  \\n• Oral or gastrointestinal mucositis that interferes with swallowing or causes \\nsevere diarrhoea   \\n• Gastrointestinal symptoms, including abdominal pain, nausea and vomiting, \\nor diarrhoea   \\n• Neurologic or mental status changes of new onset   \\n• Intravascular catheter infection, especially catheter tunnel infection  \\n• New pulmonary infiltrate or hypoxemia  \\n• Underlying chronic lung disease  \\n• Complex infection at the time of presentation : \\nInpatient status at the time of development of fever  \\nUncontroll ed or progressive cancer  \\nEvidence of hepatic insufficiency (defined as aminotransferase levels >5 times', metadata={'source': 'data/medical_oncology_handbook_june_2020_edition.pdf', 'page': 27}),\n",
       " Document(page_content='Evidence of hepatic insufficiency (defined as aminotransferase levels >5 times \\nnormal values) or renal insufficiency (defined as a creatinine clearance of <30 \\nmL/min)  \\nMultinational Association for Supportive Care in Cancer (MASCC) risk index \\nscore <21', metadata={'source': 'data/medical_oncology_handbook_june_2020_edition.pdf', 'page': 27}),\n",
       " Document(page_content='27 \\n Guide to Febrile Neutropenia  \\n \\n \\n \\nColony stimulating factors (GCSF)  are generally not recommended in management of \\nfebrile neutropaenia, with some exceptions.', metadata={'source': 'data/medical_oncology_handbook_june_2020_edition.pdf', 'page': 28}),\n",
       " Document(page_content='28 \\n Catheter -related infections  \\nCatheter removal is recommended in addition to antibiotic therapy for at least 14 days. \\nBut, if the infection is caused by coagulase -negative staphylococci and is important to \\nsave the line, catheter could be retained using systemic antibiotics.  \\nExtravasation of Chemotherapy  Drugs  8 \\nIf it d oes occur, proper documentation should include the time, site of line insertion, \\nneedle size, estimated amount of extravasated medication, technique used to manage the \\nextravasation, appearance of site, photograph, patient ’s comments, and notification of \\nphysician.  \\nManagement  \\n \\nStop infusion.  Before removing cannula attempt to aspirate some of extravasated fluid.  \\nIf antidote exists give it both IV through cannula and by SC infiltration see Table 2 below.  \\n \\nIntermittent local cooling is recommended, except for vinca alkaloids (warming packs).  \\nRest and elevate the affected site for 48 hours.  Telephone contact daily and assess need', metadata={'source': 'data/medical_oncology_handbook_june_2020_edition.pdf', 'page': 29}),\n",
       " Document(page_content='Rest and elevate the affected site for 48 hours.  Telephone contact daily and assess need \\nfor plastic surgery.  \\n \\nDay unit nurses have protocols for managing extravasatio n and their input will be \\nimportant for developing management plans.  \\n \\n8 Albanell, Joan, and Jose Baselga. \"Systemic therapy emergencies.\" Seminars in \\noncology . Vol.  27. No. 3. 2000.', metadata={'source': 'data/medical_oncology_handbook_june_2020_edition.pdf', 'page': 29}),\n",
       " Document(page_content='29 \\n Table 2 Example of Antidotes for Vesicant and Irritant Drugs  \\n \\nChemotherapy \\nagent  Pharmacologic  \\nantidote  Nonpharmacologic  \\nAntidote  Method of  \\nAdministration  \\n• Mechlorethamine  \\n(nitrogen \\nmustard)  \\n• Cisplatin  \\n(large \\nextravasation)  Sodium  \\nthiosulfate  None  Prepare 1/6 molar solution: if \\n10%Na thiosulfate solution,  \\nmix 4 mL with 6 mL sterile \\nwater for injection.  \\nThrough existing IV line, \\ninject 2 mL for every 1 mg \\nextravasated.  Inject SC if \\nneedle is removed.  \\n• Vincristine  \\n• Vinblastine  \\n• Vindesine  \\n• Etoposide  \\n• Vinorelbine  Hyaluronidase  Warm packs. 15 -20 \\nminutes at least \\nfour times/day for \\nthe first 24 -48 \\nhours and elevate  Prepare hyaluronidase, 150 \\nunits/mL with 1 -3 mL saline.  \\nInject through existing IV \\nline, 1 mL for each 1 mL \\ninfiltrated.  Inject SC if needle \\nis removed.  \\n• Doxorubicin  \\n(Adriamycin)  \\n• Daunorubicin  \\n• Idarubicin  \\n• Mitomycin C  DMSO  Ice packs  Apply cold pad with \\ncirculating ice water pack or', metadata={'source': 'data/medical_oncology_handbook_june_2020_edition.pdf', 'page': 30}),\n",
       " Document(page_content='• Idarubicin  \\n• Mitomycin C  DMSO  Ice packs  Apply cold pad with \\ncirculating ice water pack or \\ncryogel pack for 15 -20 \\nminutes at least four times/day \\nfor first 24 -48 hours.  Some \\nbenefit of 99% dimethyl \\nsulfoxide (DMSO) 1 -2 mL \\napplied to site every 6 hours.  \\n• Paclitaxel  \\n• Docetaxel  Hyaluronidase  Ice pac ks As for Vinca alkaloids.  \\n• Mechlorethamine  \\n(nitrogen \\nmustard)  \\n• Cisplatin  \\n(large \\nextravasation)  Sodium  \\nthiosulfate  None  Prepare 1/6 molar solution: if \\n10%Na thiosulfate solution, \\nmix 4 mL with 6 mL sterile \\nwater for injection.  \\nThrough existing IV line, \\ninject 2 mL for every 1 mg \\nextravasated.  Inject SC if \\nneedle is removed.  \\n• Paclitaxel  \\n• Docetaxel  Hyaluronidase  Ice packs  As for Vinca alkaloids.', metadata={'source': 'data/medical_oncology_handbook_june_2020_edition.pdf', 'page': 30}),\n",
       " Document(page_content='30 \\n PREMEDICATIONS TO PR EVENT ALLERGIC REACT IONS  \\nPaclitaxel Premedications  \\n• Recommended schedule:  \\nDexamethasone 20 mg oral, 12 hours and 6 hours before Paclitaxel (in practice \\nthe night before and the morning of treatment).  \\nPromethazine 25 mg IV 30 -60 minutes before therapy.  \\nRanitidine 50 mg IV 30 -60 minutes before therapy.  \\nAdditional Dexamethasone IV as antiemetic depending if Paclitaxel given alone \\n(4mg IV) or in combination with other drugs.  \\n \\n• Modified regimen (in cases where the patient forgets to take premedication, \\nor 2nd and subsequent cycles where no hypersensitivity reaction occurred \\nwith 1st tr eatment an d steroids are not appropriate) . 9 10 11 \\no Dexamethasone IV 20 mg 30 minutes before Paclitaxel.  \\no Promethazine IV 25 mg IV 30 -60 minutes before therapy.  \\no Ranitidine 50 mg IV 30 -60 minutes before therapy.  \\n \\n• Modified schedule for weekly regimen (where ster oids are not appropriate):  \\no  1st Treatment   \\n▪  Dexamethasone 12 mg IV .', metadata={'source': 'data/medical_oncology_handbook_june_2020_edition.pdf', 'page': 31}),\n",
       " Document(page_content='o  1st Treatment   \\n▪  Dexamethasone 12 mg IV . \\n▪ Promethazine 25mg IV . \\n▪ Ranitidine 50mg IV . \\nIf no hypersensitivity reaction, subsequent treatments may be given without \\npremedications.12 \\nDocetaxel Premedications13 \\n• Recommende d schedule for 3 weekly regimen . 14 \\nDexamethasone 8mg BD oral x 6 doses (starting night before treatment) . \\n \\n9 Product Information, 2001  \\n10 Markman M. J Clin Oncol  15(12): 3517, 1997  \\n11 Kintzel PE. Ann Pharmacother  35:1114 -7, 2001  \\n12 Quock J. Proc ASCO  18 abstr 635, 1999  \\n13 Product Information, 2001  \\n14 Jackisch C. Proc ASCO  19 abstr 417, 2000', metadata={'source': 'data/medical_oncology_handbook_june_2020_edition.pdf', 'page': 31}),\n",
       " Document(page_content='31 \\n Additional Dexamethasone IV as antiemetic depending if Docetaxel used alone \\n(4mg IV) or in combination with other drugs.  \\n• Schedule for weekly regimen:  \\nDexamethasone 8mg oral BD x 3 doses (starting night before treatment) . \\nMonoclonal Antibodies  \\n• Trastuzumab (Herceptin) may cause fever and chills, chest tightness and \\ntachycardia with 1st infusion.  \\n• Rituximab (Mabthera) may cause asthenia, chills, bronchospas m, \\nhypotension, angioedema.  Premedicate with Paracetamol 1 g QID, \\nPromethazine 25 mg IV and Hydrocortisone 200 mg IV 30 -60 minutes prior \\nto drug.  \\n• Cetuximab requires phenergan 12.5mg or 25 mg prior to infusion.', metadata={'source': 'data/medical_oncology_handbook_june_2020_edition.pdf', 'page': 32}),\n",
       " Document(page_content='32 \\n Medical Oncology Emergencies  \\n(Management of Neutropaenic fever is discussed above. ) \\nSpinal Cord -compression  \\nNeurological symptoms and signs consistent with spinal cord compression necessitates .  \\n• Urgent review and MRI of spine.  \\n• Urgent neurosurgical and or radiotherapy referral . \\n• Start Dexamethasone 8mg IV stat , followed by 16 -24 mg daily in divided \\ndoses.  \\nSVC Obstruction:  \\n• If the patient presents with st ridor or respiratory compromise , emergency \\ntreatment with endovascular stent and Radiotherapy is required.  \\n• In other cases: a histologica l diagnosis is required prior to initiating specific \\ntreatment.  \\n• In chemotherapy -sensitive malignancies like small –cell lung cancer, germ \\ncell tumour or lymphoma, systemic chemotherapy is usually t he treatment. In \\nmost other tum ours, including non -small c ell lung cancer, Radiotherapy is the \\npreferred treatment.  \\n• Endovascular stenting could achieve rapid relief of symptoms.  \\nHypercalcemia:', metadata={'source': 'data/medical_oncology_handbook_june_2020_edition.pdf', 'page': 33}),\n",
       " Document(page_content='• Endovascular stenting could achieve rapid relief of symptoms.  \\nHypercalcemia:  \\n• Saline hydration, IV zelodronic acid, IV frusemide after adequate hydration . \\n• Steroids useful in hypercalcaemia due to lym phoma . \\n• s/c calcitonin may be useful in resistant hypercalcemia . \\nInfusion reactions and other acute reactions  \\n• Mild to moderate infusion reactions with no features of anaphylaxis -  \\n• IV hydrocortisone and phenergan. Stop infusion till reaction subsides and \\nrestart at a lower rate, with close monitoring.  \\nSevere infusion reactions and anaphylaxis (hypotension, angioedema,  \\nbronchospasm, generalised urticaria)  - Resuscitation  with epinephrine, \\nhydrocortisone,  phenergan ranitidine and fluids.  \\nDO NOT RE -CHALLENGE.', metadata={'source': 'data/medical_oncology_handbook_june_2020_edition.pdf', 'page': 33}),\n",
       " Document(page_content='33 \\n SUMMARY OF MANAGEMEN T OF COMMON CANCERS  15 16 \\nThis section outlines the principles behind the management of common cancers.  \\nFor metastatic cancers, enrolment into a clinical trial is the best treatment option.  \\nSummaries provided below are developed using eviQ and NCCN guidelines as practical \\nguidance.  \\n \\n \\nBREAST CANCER  \\nEarly breast cancers:  \\n(Includes axillary node positive disease .) \\n• Mostly curative intent therapy.  \\nPost-operative systemic treatment depends on oestr ogen and/ or progestogen \\nreceptor status, Her 2 st atus and the estimated risk of systemic relapse.  \\n• Prognostic factors.  \\nSize, age, grade, axillary nodes, receptor status and lympho -vascular invasion.  \\n \\n Low risk  Average risk  High risk  \\nSize <1cm  1-2 cm  >2 cm \\nAge   <35 \\nNodes  Negative   Positive  \\nGrade  Grade 1  Grade2  Grade3  \\nER/PR  Positive   Negative  \\nHer2  Negative   Positive  \\nLVI Absent  present   \\n \\n• Low risk  - Hormonal manipulation or nil.', metadata={'source': 'data/medical_oncology_handbook_june_2020_edition.pdf', 'page': 34}),\n",
       " Document(page_content='Her2  Negative   Positive  \\nLVI Absent  present   \\n \\n• Low risk  - Hormonal manipulation or nil.  \\n• Average  - Hormonal +/ - chemotherapy for ER/PR positive disease,  \\n \\n15 www.nccn.org . \\n16 www.eviq.org.au', metadata={'source': 'data/medical_oncology_handbook_june_2020_edition.pdf', 'page': 34}),\n",
       " Document(page_content='34 \\n  Chemotherapy for ER/PR negative disease.  \\n• High risk - Chemotherapy + hormonal manipulation for ER positiv e disease.  \\nChemotherapy for ER/PR negative disease.  \\n• For Her-2 positive disease , Herceptin is given with chemotherapy for total of \\n52 weeks (3 weekly).  \\n• Hormonal manipulation -  \\nIn premenopausal women; Tamoxifen alone may be an option . In patients who \\nremain premenopausal after che motherapy  and have high risk disease , ovarian  \\nsuppression with LHRH agonists or bilateral oophorectom y with exemestane or \\nTamoxifen is better than Tamoxifen alone.  Aromatase Inhibitors are not used \\nalone in premenopausal women.  \\nConsider 10 years of tamoxifen over 5 years of treatment, particularly f or patients \\nat highest baseline risk eg where chemotherapy was indicated.  \\nIn post -menopausal women  - Aromatase inhibitors are the preferred endocrine \\ntreatment unless contraindicated. In patients who cannot tolerate AI or where it is', metadata={'source': 'data/medical_oncology_handbook_june_2020_edition.pdf', 'page': 35}),\n",
       " Document(page_content='treatment unless contraindicated. In patients who cannot tolerate AI or where it is \\ncontraindicated, Tamox ifen is used.   \\nIn post -menopausal patients who start treatment with tamoxifen, switching to AI \\nafter 2 -3 years is recommended.  \\n5-10 additional years of aromatase inhibitors after 5 years of tamoxifen improves \\nsurvival in high -risk patients.  \\nFor patients on AIs and documented osteopaenia addition of bisphosphonates  \\ndecreases the risk of decline in bone density.  They are also encouraged to take \\nregular calcium and vitamin D tablets.  DEXA scans are done yearly to two yearly \\nfor monitoring bone  health in patients on aromatase inhibitors.  \\nChemotherapy regimens - \\n• Lower risk/Average risk - 4x TC,  \\n• High risk - 3x FEC - 3x D OR  AC-weekly Taxol  OR AC - dd Taxol . AC may \\nbe given in dose dense fashion (preferred if possible).  \\n• In Her-2 positive disease , Trast uzumab  is combined with Taxanes and not', metadata={'source': 'data/medical_oncology_handbook_june_2020_edition.pdf', 'page': 35}),\n",
       " Document(page_content='• In Her-2 positive disease , Trast uzumab  is combined with Taxanes and not \\nwith anthracyclines because of risk of cardiac toxicity. Eg FEC -D Herceptin \\nor AC -Taxol Trastuzumab .  Pertuzumab may be added in treatment given \\nneoadjuvantly.  \\n• In Her2 positive disea se, a non -anthracycline regimen , eg TCarboH is an  \\nalternative .17 \\n \\n17 Slamon, D., W. Eiermann, et al. (2011). \"Adjuvant trastuzumab in HER2 -positive \\nbreast cancer.\" New England Journal of Medicin e 365(14): 1273 -1283', metadata={'source': 'data/medical_oncology_handbook_june_2020_edition.pdf', 'page': 35}),\n",
       " Document(page_content='35 \\n • G-CSF prophylaxis - If severe neutropenia, cycles delayed because of \\nneutropenia or complicated by neutropenic fever, add neulasta  (most of these \\nprotocols now have upfront G -CSF)    \\nNeoadjuvant chemotherapy:  \\n• Chemotherapy regim ens are similar to adjuvant regimens.  \\n• More effective in triple negative or Her -2 positive disease.  \\n• May be used to achieve breast conservation in some cases, large primary \\ntumour sizes, clinical nodal involvement (locally advanced disease) or if \\nsurgical c oncerns for upfront surgery.  \\n• Patients with residual cancer after neoadjuvant chemotherapy may require \\nfurther chemotherapy treatment or a change in agent (eg capecitabine if triple \\nnegative, TDMI (trastuzumab emtansine) if HER2 positive).  \\nPost -operative  radiotherapy:  \\n• After lumpectomy, radiotherapy decreases local recurrence rates.  \\n• After mastectomy, indications include (but not limited to):  \\no close or positive margins  \\no >/=4 axillary nodes involved', metadata={'source': 'data/medical_oncology_handbook_june_2020_edition.pdf', 'page': 36}),\n",
       " Document(page_content='o close or positive margins  \\no >/=4 axillary nodes involved  \\no tumour size >5 cm  \\n• Extensive lymphovascular inva sion.  \\nRadiotherapy is given after the chemotherapy is completed, but can occur \\nconcurrently with Herceptin in Her2 positive disease  \\nLocally advanced and inflammatory breast cancers  \\n• The cure rate is lower than with early breast cancers.  \\n• Chemotherapy is giv en before surgery to reduce the size of the primary and \\neradicate micrometastases (see above for regimens).  \\n• Radiotherapy is given after surgery.  \\nMetastatic breast cancer  \\n• First line ER/PR + HER2 - bone only metastases - Endocrine therapy +/ - CDK \\n4/6 inhibitor (eg palbociclib or ribociclib) . \\n• Patients with bone metastases also benefit from monthly Bisphosphonates or \\nDenosumab to reduce pain, skeletal events and hypercalcemia.  \\n• First line chemotherapy is  usually Taxane or Anthracycline based (depending \\nupon chemotherapy exposure in adjuvant setting) with combination therapies', metadata={'source': 'data/medical_oncology_handbook_june_2020_edition.pdf', 'page': 36}),\n",
       " Document(page_content='36 \\n generally reserved for patients with high volume disease (including visceral \\ndisease) or suggestion of aggressive clinical course . \\nLater lines of therapy can include taxanes, gemcitabine, capecitabine, \\nvinorelbine and eribulin.  Choices may be influenced by patient and physician \\npreferences, previous chemotherapy exposure and patient fitness.  For further \\ndetailed information on these  protocols , visit eviQ website.  \\n• In Her 2 positive disease, Taxanes can be combined with Trastuzumab  and \\nPertuzumab as initial treatment.  \\nSecond line treatment may include TDM1 (Trastuzumab emtansine ). If \\nprogression on TDM -1, use Lapatanib/capecitabine a nd Herceptin/ \\nchemotherapy .', metadata={'source': 'data/medical_oncology_handbook_june_2020_edition.pdf', 'page': 37}),\n",
       " Document(page_content='37 \\n Cancers of the Gastro -Intestinal Trac t \\nAnal Cancer  \\n \\nMajority of patients are treated with concurrent chemo -radiation. This requires PICC \\ninsertion and CADD pump for delivery of continuous infusion 5 - Fluorouracil.  \\n \\nRegimen:  \\nMitomycin C on Day 1 and 5 -Fluorouracil on Days 1 to 4 and 29 to 32 along \\nwith radiation for 5 -6 weeks  (standard of care).  \\n \\nMitomycin C can be substituted with Cisplatin  (if patient has hypersensitivity to \\nmitomycin or has any coagulation or bleeding disorders or thrombocytopenia).  \\nIf patient cannot have PICC for some reason 5 -Fluorouracil can be substituted \\nwith Capecitabine.  \\n \\nMetastatic Anal Cancer: Different chemother apies can be used such as, \\nCarboplatin & Paclitaxel (weekly/three weekly), 5Fu & Cisplatin, FOLCIS \\n(5Fu, leucovorin & Cisplatin), mFOLFOX, mDCF.  \\n \\nGastro -Oesophageal and Gastric Cancer  \\n \\nDefinitive Concurrent Chemo -Radiation  \\n \\nFor those not suitable for surgery:', metadata={'source': 'data/medical_oncology_handbook_june_2020_edition.pdf', 'page': 38}),\n",
       " Document(page_content='Definitive Concurrent Chemo -Radiation  \\n \\nFor those not suitable for surgery:  \\nCisplatin and 5 -Fluoruracil along with radiation (2 cycles)  \\n \\nNeo-adjuvant  chemoradiation : \\n \\nWeekly Carboplatin and Taxol  \\nAlternatively, Cisplatin and 5 -Fluorouracil with radiation.  \\n \\nPeri-operative chemotherapy : \\n \\nFor aden ocarcinoma of lower oesophagus, gastro -oesophageal junction and stomach.  \\n4 cycles FLOT pre and post resection.  \\nor, 3 cycles of ECF / EOX  pre and post resection . \\nor 2 x cis/5fu pre & post resection.  \\n \\nAdvanced or Metastatic Carcinoma of Gastro -oesophageal J unction/Stomach:  \\n \\nDifferent single agent/combination regimens can be used depending on existing co -\\nmorbidities. Many regimens can be used for both adenocarcino and squamous cell \\ncarcinoma.  \\nCombination : FOLFOX 6  or XELOX  \\nSingle agents:  Docetaxel, paclitaxel, irinotecan  \\n \\nFor HER -2 positive adenocarcinoma – Add Trastuzumab (Herceptin).', metadata={'source': 'data/medical_oncology_handbook_june_2020_edition.pdf', 'page': 38}),\n",
       " Document(page_content='38 \\n  \\nCERS OF THE GASTRO -INTESTINAL TRAC  \\nBiliary and Gall Bladder  \\nOutcome is usually poor in patients with multiple co -morbidities and poor performance \\nstatus. In these cases, omitting chemotherapy from management plans may be prudent.  \\n• Adjuvant therapy for node positive disease – fluoropyrimidine or Gemcitabine \\nbased chemotherapy (eg: Cisplatin or Carboplatin /Gem citabine).  \\nConsider chemoradiati on for margin -positive or node positive cancer.  \\n• Metastatic/inoperable – Same regimens as adjuvant therapy.  \\nHepatocellular carcinoma  \\n• Limited disease: Operable or locoregional therapy available  \\n• Inoperable  or not suitable for locoregional therapy:  Lenvatinib  or Sorafenib  \\nin Child -Pugh A patients) . Role of systemic chemotherapy is not established.  \\n \\nMetastatic Neuro -endocrine Tumours of Gastro -intestinal Tract  \\n• Grade I/II – Sandostatin/Lanreotide . On progression capecitabine and \\ntemozolomide.', metadata={'source': 'data/medical_oncology_handbook_june_2020_edition.pdf', 'page': 39}),\n",
       " Document(page_content='• Grade I/II – Sandostatin/Lanreotide . On progression capecitabine and \\ntemozolomide.  \\n      Everolimus or sunitinib can be used for pancreatic Grade I/II tumours.  \\n• Grade III – Carboplatin and etoposide or cisplatin and etoposide .  \\nAdeno -carcinoma of Pancreas  \\nRole of neoadjuvant therapy contin ues to evolve, and this is usually not standard practice \\noutside of clinical trial settings except where an MDT strongly recommends this \\napproach. Outcome is usually poor in patients with multiple co -morbidities and poor \\nperformance status. In these cases,  omitting chemotherapy from management plans may \\nbe prudent.  \\n \\n• Adjuvant – modified FOLFORINOX x 6 months or Capecitabine + \\nGemcitabine . \\n• Advanced/metastatic – If disease recurrence occurs after 6 months of \\ncompleting adjuvant therapy, same regimen could be c onsidered. In good \\nperformance patients with minimal co -morbidities, m FOLFIRINOX or', metadata={'source': 'data/medical_oncology_handbook_june_2020_edition.pdf', 'page': 39}),\n",
       " Document(page_content='performance patients with minimal co -morbidities, m FOLFIRINOX or \\nGemcitabine and nab -Paclitaxel.  After 4 -6 months, less intensive components \\ncould be maintained.', metadata={'source': 'data/medical_oncology_handbook_june_2020_edition.pdf', 'page': 39}),\n",
       " Document(page_content='39 \\n In poor performance patients, BSC alone or single agent  regimens such as \\ngemcitabine  may be appropriate.  \\n \\n \\n Colon Cancer  \\nStage I and II surgery alone.  \\nStage II with adverse features is  treated as stage III with adjuvant chemotherapy. \\nAdverse features are – poorly differentiated histology, lympho -vascular invasion, \\nbowel obstruction, perforation, fewer than 12 lymph nodes in the resected \\nspecimen, perineural invasion, close or positive m argins.  \\nAdjuvant chemotherapy  is for six months. However, in low risk patients (T1 -3 \\nN1) shorter duration (three months) of adjuvant XELOX (CAPOX) is equivalent \\nto six months of XELOX in efficacy with less neurotoxicity . If using mFOLFOX \\nrecommendation is for six months of treatment. For High risk features, \\nrecommendation is for six months of treatment.  \\nRegimens : Different schedules of calcium leucovorin and 5 fluorouracil, \\nCapecitabine, FOLFOX  & XELOX .', metadata={'source': 'data/medical_oncology_handbook_june_2020_edition.pdf', 'page': 40}),\n",
       " Document(page_content='Capecitabine, FOLFOX  & XELOX . \\nMetastatic cancer : Any adjuvant regimen can be used in metastatic setting. Other \\nregimens are Irinotecan, FOLFIRI, FOLFOXIRI, XELIRI.  \\nAssess patients with imaging after 3 cycles of chemotherapy for respectability  of \\nlesions. Discuss  in GI multi -disciplinary meetings. Some of the patients with few \\nmetastases ma y eventually be curable.  \\nBevacizumab is usually combined to different chemotherapy regimens in \\nmetastatic setting unless contra -indicated.  \\nPatients with KRAS wild type tumours have additional option of having \\nCetuximab/ Panitumumab added  to chemotherapy re gimen.  \\n \\nRectal Cancer  \\nMost of the patient s are treated with neo -adjuvant concurrent chemo -radiotherapy.  \\nChemotherapy consists of continuous infusion 5 -Fluorouracil through PICC line or oral \\ncapecitabine. If the patient did not receive neo -adjuvant treatmen t it may be given post -\\noperatively for T3/T4 or node positive tumours.', metadata={'source': 'data/medical_oncology_handbook_june_2020_edition.pdf', 'page': 40}),\n",
       " Document(page_content='40 \\n For those who had neo -adjuvant treatment further adjuvant chemotherapy is offered post -\\noperatively in the form of leucovorin -5-Fluorouracil/capecitabine  to complete six months \\nof perio perative chemotherapy.  \\nFOLFOX is currently not approved for rectal cancer.  \\n \\nMetastatic rectal cancer  \\nAll the regimens used in colonic cancer can be used in metastatic rectal cancer including \\nBevacizumab, cetuximab and panitumumab.  \\nAssess patients with imag ing after 3 cycles of chemotherapy for res ectability of \\nlesions. Discuss  in GI multi -disciplinary meetings. Some of the patients with few \\nmetastases may eventually be curable.  \\n \\nGastro-Intestinal Stromal Tumours (GIST)  \\n• Adjuvant  – for those with high risk features – Imatinib for 3 years . \\nHigh Risk Features are : Primary GIST greater than 5 cm with a mitotic count of \\ngreater than 5/50 high power fields (HPF); or  \\nPrimary GIST greater than 10 cm with any mitotic rate; or', metadata={'source': 'data/medical_oncology_handbook_june_2020_edition.pdf', 'page': 41}),\n",
       " Document(page_content='Primary GIST greater than 10 cm with any mitotic rate; or  \\nPrimary GIST with a mitotic count of greater than 10/50 HPF  \\n• Metastatic  -   Imatinib. Sunitinib can be used when progress on Imatinib.', metadata={'source': 'data/medical_oncology_handbook_june_2020_edition.pdf', 'page': 41}),\n",
       " Document(page_content='41 \\n GBM  \\n• Surgery is for resectable disease.  \\n• For resected GBM, Temazolamide with RT and 4 weeks later, 5days per \\nmonth for 6 m onths of Temazolamide improves survival.   \\nTemazolamide:  \\n• With RT - 75mg/m2/day M -F. \\n• After RT or on its own for palliation - 150-200 mg/m2/day for 5 days a \\nmonth.  \\nCheck platelets mid cycle as a caution.  \\nUnresectable and incurable GBM - options include Temazolam ide & Avastin \\nbased combinations.  \\nGERM CELL TUMOURS   \\nStage 1 -   \\n• Normally for stage 1 seminoma  (make sure serum AFP normal)  - Single \\ndose carbo platin AUC 7.  Check counts every week for 2 weeks post  \\nchemotherapy . \\nDiscuss sperm banking  with patient prior to g iving chemotherapy. However , \\nfertility is unlikely to be affected  with one cycle of carboplatin.  \\n• For stage 1 non -seminoma - wait and watch (6 weekly markers and 3 \\nmonthly CTs first 2 years and later relax to 6 monthly scans and 3 monthly \\nbloods for another 3 years).', metadata={'source': 'data/medical_oncology_handbook_june_2020_edition.pdf', 'page': 42}),\n",
       " Document(page_content='bloods for another 3 years).  \\nor 2 cycles of BEP for patients who are not reliable for follow up  or who move \\naround different towns . \\nStage 2 onwards -  \\nThis includes patients with normal scans but have the markers eleva ted few weeks \\npost orchidectomy.  \\nSeminoma:  \\n• Stage 2 or stage 3: \\nGood prognosis - 3 cycles of BEP . \\nIntermediate prognosis - 4x cycles of BEP ( only first 3 cycles are with Bleomycin).  \\n• Non seminoma   \\nGood prognosis - 3 x cycles of BEP,', metadata={'source': 'data/medical_oncology_handbook_june_2020_edition.pdf', 'page': 42}),\n",
       " Document(page_content='42 \\n Intermediate or poor prognosis - 4x cycles of BEP.  \\nResidual disease /mass  after optimal chemotherapy needs to be resected.  \\nPre BEP treatment:  \\n• History of renal, auditory,  neuropathy and vascular issues,  \\n• Lung function test - DLCO and lung volumes,  \\n• Sperm banking  (Semen cryopreservation: In Townsville, this is performed by \\nQFG) , ELFTS, FBC, LDH and markers.  \\n(Please discourage smoking ). \\n• Recurrent GCTs can still be cured by TIP or VIP chemotherapy.  \\nPrognostic groups:  Seminoma:  \\n \\n Good prognosis  Intermediate prognosis  \\nPrimary site  any any \\nPresence of non \\npulmonary met astasis no yes \\nMarkers  (not AFP)  any any \\n \\nIf serum  AFP  is elevated, it is treated as non -seminoma.  \\nNon -Seminoma:  \\n \\n Good  Intermediate  Poor  \\nPrimary site  Non mediastinal  Non mediastinal  mediastinal  \\nNon pulmonary \\nmetastasis no no yes \\nMarkers   \\nAFP <1000  1000 -10000  >10000  \\nB HCG  <5000  5000 -50000  >50000  \\nLDH  <1.5 x ULN  1.5-10 x ULN  >10 x ULN', metadata={'source': 'data/medical_oncology_handbook_june_2020_edition.pdf', 'page': 43}),\n",
       " Document(page_content='43 \\n  \\nHEAD AND NECK CANCER  \\n• Resectable disease - Surgery.  \\nFor high risk disease, post op radiotherapy with chemotherapy improves survival.  \\n• Unresectable  disease or organ preservation -  \\nInduction chemotherapy followed by chemoradiotherapy.  \\nInduction chemotherapy - 2 -3 cycles of T PF. \\nChemoradiotherapy - weekly cisplatin 40mg/m2.  \\n• *If not fit for weekly cisplatin , abnormal renal function or cardiac issues -  \\nCetuximab ( Erbitux ) Loading dose 400mg/m2 one week prior to RT and then \\nweekly 250mg/m2 weekly  (Discuss with Radiation oncologists for their \\npreference ). \\nThey need Phenergan 12.5mg or 25mg as premed ications .  \\n• Metastatic H&N cancer - (Cisplatin or Carboplatin) and 5FU / Capecitabine  \\nSecond -line -PDL1 antibody Nivolumab.  \\nLUNG CANCER  \\n• Non Small Cell Lung cancers:  \\n*Stage I to III - Surg ical resection  offers the best chance of cure.  \\n• For resected stage 1b, II or III  -', metadata={'source': 'data/medical_oncology_handbook_june_2020_edition.pdf', 'page': 44}),\n",
       " Document(page_content='• For resected stage 1b, II or III  -  \\nAdjuvant chemotherapy with cisplatin  & vinorelbine x 4 cycles to improve \\nsurvival in fit and <70 years.  Carboplatin & paclitaxel  is other alternative.  \\n• *Stage III - \\nFor patients who are unresectable, chemo -radiation can improve survival.  \\n• concurrent with radia tion-  \\nCisplatin with Etoposide is the preferred regimen. Other alternativ es are used in \\npatients who are unfit for Cisplatin (elderly, renal impairment etc) . \\nEg - Carbo platin (AUC 2) and Paclitaxel (50mg.m2) weekly with radiation.   \\nPost CRT immunotherapy improves outcomes.  \\n \\nNon metastatic pan coast tumours  - chemo -radiotherapy followed by surgery.  \\n• *Stage IV or incurable stage III b-  \\nAlways test for oncogenic mutations like EGFR , ALK  and ROS -1 in Non \\nSquamous  NSCLC. If either is positive, treat with EGFR inhibitor ( Afatinib is', metadata={'source': 'data/medical_oncology_handbook_june_2020_edition.pdf', 'page': 44}),\n",
       " Document(page_content='44 \\n preferred or Erlotinib or Gefitinib) or ALK inhibitor (Alectinib is preferred or \\nCrizotinib ).  \\n• All NSCLCs (non squamous or squamous) should also be tested for PDL -1 by \\nIHC (to check for eligibility of using immunotherapy alone as first line treatment). \\nIf PDL -1 expression >50%  and there is no actionable mutation , then single agent \\nPembrolizumab (anti PDL -1) can be offered as upfront treatment (without \\nchemotherapy).  \\n• For NSCLC patients with PDL -1 expression less than 50% and  with no actionable \\nmutation, consider offering combination of immunotherapy (anti PDL -1) along \\nwith platinum doublet chemotherapy if performance status is reasonable (ECOG \\n<=2) . \\n• Maintenance Pemetrexed  chemotherapy can be considered in patients with Non \\nSquamous  NSCLC who have not progressed after first line combination \\ntreatment.  \\n• All these patients with incurable disease should be considered for clinical trial if \\none is available.', metadata={'source': 'data/medical_oncology_handbook_june_2020_edition.pdf', 'page': 45}),\n",
       " Document(page_content='one is available.  \\n• In select  patient  groups (e.g elderly with good PS, or patients who have \\ncontraindication for immunotherapy like significant autoimmune disorder), single  \\nagent chemotherapy alone is a reasonable option  \\nOnce first line treatment with chemotherapy fails – consider treatment with  anti \\nPDL -1 antibody  (e.g Nivolumab) for 2nd line treatment.  \\n• Palliative best supportive care is reasonable for patients with poor (ECOG>2) PS. \\nConsider early referral to palliative care for all stage IV lung cancer patients \\nundergoing active treatment as this has shown to improve survival.  \\nSmall cell lung cancer  \\n• Limited stage -  \\nCisplati n and etoposide x 4 cycles and radiation as early as possible or Carboplatin \\nand etoposide for 6 cycles and radiation.  \\nAt the end of the treatment, if no brain mets - Prophy lactic cranial irradiation to \\nadd another 5% survival benefit.  \\n• Extensive stage -', metadata={'source': 'data/medical_oncology_handbook_june_2020_edition.pdf', 'page': 45}),\n",
       " Document(page_content='add another 5% survival benefit.  \\n• Extensive stage - \\nCarboplatin and etoposide with immunotherapy for 6 cycles. If complete response \\nthat last for 6 -12 months, could have re treated.  \\n• Urgent chemotherapy (with or without  tumour ly sis prophylaxis ) for patients \\npresenting with bulky disease and oncology emergency (e.g SVC obstruction).', metadata={'source': 'data/medical_oncology_handbook_june_2020_edition.pdf', 'page': 45}),\n",
       " Document(page_content='45 \\n Mesothelioma  \\nSurgical decortication can be useful in selected patients.  \\nOtherwise, Carbo AUC 5 or Cisplatin and Pemetrex ed every 3 weeks.  \\nImportant - 1 week before Pemetrex ed - start VitB12 1000mcg IM every 9 \\nweeks and folic acid 0.5 mg daily until Pemetrex ed is stopped.  \\nConsider Clinical trial for these patients if available.  \\n \\n \\n \\n \\nMELANOMA  \\n• Stage I to III - resection of the primary +/ - sentine l node biopsy and node \\ndissection for node positive disease.  \\no Stage IB or II can be considered for clinical trial with adjuvant \\ntreatment if available otherwise ongoing surveillance.  \\n• For stage III disease : \\no Stage IIIA disease: consider imaging and BRAF muta tion testing. \\nConsider systemic treatment on clinical trial, otherwise surveillance.  \\no Resected stage IIIB/C/D disease: imaging to confirm staging and \\nBRAF mutation testing. Immunotherapy  (anti PD -1) for BRAF WT \\ndisease, or Dabrafenib (BRAFi) and Trametinib (MEKi) for patients', metadata={'source': 'data/medical_oncology_handbook_june_2020_edition.pdf', 'page': 46}),\n",
       " Document(page_content='disease, or Dabrafenib (BRAFi) and Trametinib (MEKi) for patients \\nwith BRAF V600 mutation. Observation is also an option. Treatment \\nsubject to ECOG 1 or less.  \\no Unresectable stage III disease: treat as unresectable stage IV disease.  \\no Consider adjuvant radiotherapy in patients with involved surgical \\nmargi ns. \\n• Stage IV disease  \\no Limited/oligometastatic (resectable) disease. Imaging to confirm \\nstaging. BRAF mutation testing. LDH. Systemic treatment followed \\nby imaging and resection OR resection followed by systemic \\ntreatment.  \\n▪ Systemic treatment depending on BR AF and performance \\nstatus.  \\n▪ Systemic options are the same as resected stage III disease', metadata={'source': 'data/medical_oncology_handbook_june_2020_edition.pdf', 'page': 46}),\n",
       " Document(page_content='46 \\n o Disseminated (unresectable) disease.  \\n▪ In patients without brain metastasis: systemic therapy as \\nabove, intralesional T -VEC, palliative resection or RT. Best \\nsupportive care.  \\n▪ With brain metastasis: Primary RT , Palliative resection with or \\nwithout adjuvant RT , Followed by systemic therapy as above  \\nor combination immunotherapy in low volume cases .', metadata={'source': 'data/medical_oncology_handbook_june_2020_edition.pdf', 'page': 47}),\n",
       " Document(page_content='47 \\n GYNAECOLOGICAL CANCER  \\n• Ovarian cancer  \\nStage 1 - Surgery  (adjuvant chemotherapy for high risk patients such as with \\ntumour rupture or positive peritoneal washings) . \\nStage >/= 2 Debulking surgery, BSO/TAH.  \\nPost debulking su rgery - Carbo AUC 5/6 and Taxol weekly or three weekly  (three \\nweekly generally prefe rred) .   \\nPatients who are unfit for surgery can be given neo adjuvant chemotherapy first \\nand receive surgery after several cycles of chemotherapy (interval debulking) with \\nsubsequent adjuvant chemotherapy.  This approach may reduce surgical morbidity \\nof de bulking procedures without compromising outcomes.  \\nIntraperitoneal chemotherapy may be used in selected stage3 disease, after \\noptimal debulking surgery.  \\nIn patients who have metastatic disease (stage 4) or those who do not achieve \\noptimal debulking (residua l disease >1cm), bevacizumab for one year may be \\nused on the PBS.   \\n \\n• Relapsed Disease', metadata={'source': 'data/medical_oncology_handbook_june_2020_edition.pdf', 'page': 48}),\n",
       " Document(page_content='used on the PBS.   \\n \\n• Relapsed Disease  \\nChoice of agent may depend upon interval since last exposure to platinum (ie \\nplatinum sensitive versus resistant).  \\nNewer agents such as PARP inhibitors may be used depending upon BRCA \\nmutation status . \\nProtocols include carboplatin/caelyx, carboplatin/gemcitabine and topotecan . \\nCervical cancer  \\n• Early disease - surgery  \\n• Locally advanced - chemoradiotherapy with weekly cispla tin, \\n• Metastatic - Platinum/ Taxol / Bevacizumab , Taxol/Topotecan , Gemcitabine .', metadata={'source': 'data/medical_oncology_handbook_june_2020_edition.pdf', 'page': 48}),\n",
       " Document(page_content='48 \\n CANCERS OF GENITO URINARY SYSTEM  \\nPROSTATE CANCER  \\nTreatment depends on disease stage and hormone sensitivity.  \\n \\n• Early stage disease  is treat ed with surgery, radiotherapy ( externa l beam and/ \\nor brachytherapy) or observation. Treatment modality is individualised based \\non several factors: age and co morbidities of the patient, serum PSA level, \\nGleeson score, clinical stage and patient preference based on benefits and \\nside effects of therapy.  \\nFor example, a patient with clinically non apparent tumour with Gleason score of \\n<6 who has a life expectancy of <10 years coul d be actively observed without any \\nimpact on survival.  \\nFor locally advanced inoperable disease, radical radiotherapy cou ld lead to cure. \\nAndrogen deprivation therapy is sometimes used for short periods  (4-6 months) \\nbefore/concomitantly/ after radiotherapy in selected high-risk patients.  \\n \\nMetastatic disease  is incurable and the aims are to prolong survival and improve \\nquali ty of life.', metadata={'source': 'data/medical_oncology_handbook_june_2020_edition.pdf', 'page': 49}),\n",
       " Document(page_content='quali ty of life.  \\n \\nHormone Sensitive disease:  \\n• All Hormone sensitive tumours are treated with a GnRH agonist  (eg- \\ngoserelin,  leuprorelin). To prevent flare, antiandrogens  (eg- flutamide,  are \\nstarted 1-2 weeks before the injection  and continued for a total of 3-4 weeks ). \\nWhether anti - androge ns are continued beyond that is  controversial.  \\n• Chemotherapy wi th Docetaxel 75 mg/m2 x 6 doses , can be added to \\nhormonal therapy  in fit patients with high volume (presence of visceral mets \\nor >= 4 bony mets)  metas tatic disease, as it improves survival significantly \\n(CHAARTED, STAMPEDE trials).  \\nHormone Refractory disease:  \\n• Hormone refractory disease includes patients where the disease has \\nprogressed despite hormonal manipulation.  GnRH agonists are usually \\ncontinued.    \\n• Chemotherapy improves median survival by up to 3 months and maintains \\nimprovement in quality of life.   \\n• Bone metastases are treated with intravenous bisphosphonates  (eg-zoledronic', metadata={'source': 'data/medical_oncology_handbook_june_2020_edition.pdf', 'page': 49}),\n",
       " Document(page_content='• Bone metastases are treated with intravenous bisphosphonates  (eg-zoledronic \\nacid) or RANK -ligand inhibitor Denosumab monthly.  For asymptomatic and \\nlow volume disease, chemotherapy is usually delayed.', metadata={'source': 'data/medical_oncology_handbook_june_2020_edition.pdf', 'page': 49}),\n",
       " Document(page_content='49 \\n • Symptomatic metastases or rapid rise in PSA (doubling time of <3 months) \\nmay be treated with docetaxel  (75mg/m2)  and prednisone  5 mg BD.  On \\nprogression after doc etaxel, newer androgen inhibitors (below) are effective.  \\nPalliative care is another option.  \\n• Localised bone pain responds to external beam radiotherapy very well. Men \\nwith multifocal painful bone metastases and those with persistent or recurrent \\npain despite receiving EBRT to maximal normal tissue tolerance may achieve \\npalliation of their symptoms by treatment with bone -targeted radi oisotopes \\nsuch as strontium -89. \\nDisease progression after chemotherapy : Abiraterone , an andr ogen biosynthesis \\ninhibitor or Enz alutamide an androgen receptor signalling inhibitor are effective . Median \\nprogression free survival and overall survival are better compared to placebo.  \\nRenal Cell Carcinoma  \\n• Metastatic renal cell carcino ma with clear cell  histology is  treated based on', metadata={'source': 'data/medical_oncology_handbook_june_2020_edition.pdf', 'page': 50}),\n",
       " Document(page_content='• Metastatic renal cell carcino ma with clear cell  histology is  treated based on \\nrisk stratification  (example IMDC criteria) . \\n• Low risk disease can be treated with tyrosine kinase inhibitors Sunitinib  or \\nPazopanib. Cabozantinib or Sorafenib can be used after failure of these. \\nSorefenib can also be used for  papillary carcinoma. Everolimus and axitinib \\nare other second line options available.  \\n• Intermediate and high -risk disease is treated with combination \\nimmunotherapy Ipilimumab (anti CTLA4) and Nivolumab (anti PDL -1). \\n• Once progressed on first like VEGF TKI, immunotherapy is drug of choice \\nfor second line treatment. Vice versa if disease progresses on immunotherapy \\nthen VEGF TKI such as Cabozantinib or Sunitinib or Pazopanib can be used.  \\nUrinary Bladder Cancer  \\n• Non-muscle invasive disease is treated with surger y and adjuvan t intravesical \\ntherapies (eg.  BCG  or Mitomycin ). \\n• Muscle invasive disease is treated with surgery. Pre -op Cisplatin based (neo-', metadata={'source': 'data/medical_oncology_handbook_june_2020_edition.pdf', 'page': 50}),\n",
       " Document(page_content='• Muscle invasive disease is treated with surgery. Pre -op Cisplatin based (neo-\\nadjuvant) chemotherapy improves survival.  \\n• Adjuvant Cisplatin based Chemotherapy is considered for those at high ris k \\nof recurrence such as T3/T4 tumours, lympho -vascular invasion or positive \\nnodes  if neo -adjuvant therapy was not given .  \\n \\nInoperable disease may be managed with:  \\n• Radiotherapy with or without radio -sensitising chemotherapy with weekly \\ncisplatin or mitomyci n and infusional 5 -Fluorourcil.', metadata={'source': 'data/medical_oncology_handbook_june_2020_edition.pdf', 'page': 50}),\n",
       " Document(page_content='50 \\n • Chemotherapy alone (platinum and gemcitabine), or a  \\n• Palliative care alone.  \\n \\nMetastatic disease  is managed with chemotherapy , immunotherapy  or palliative care \\nalone.  \\nPlatinum based chemotherapy is usually  the first line palliative treatment. One such \\nregimen is Carboplatin and Gemcitabine.   \\n \\nImmunotherapy with Pembrolizumab is used as second line treatment after failure of \\nplatinum -based  chemotherapy.', metadata={'source': 'data/medical_oncology_handbook_june_2020_edition.pdf', 'page': 51})]"
      ]
     },
     "execution_count": 5,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "texts"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 6,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Vector DB Successfully Created!\n"
     ]
    }
   ],
   "source": [
    "\n",
    "url = \"http://localhost:6333\"\n",
    "qdrant = Qdrant.from_documents(\n",
    "    texts,\n",
    "    embeddings,\n",
    "    url=url,\n",
    "    prefer_grpc=False,\n",
    "    collection_name=\"vector_db\"\n",
    ")\n",
    "\n",
    "print(\"Vector DB Successfully Created!\")\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "Python 3",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.10.13"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 4
}
